var title_f6_50_6944="Short axis left main CA";
var content_f6_50_6944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Short axis view of left main coronary artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 203px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis view, with the imaging plane through the aortic root (AO) just above the aortic valve, demonstrates the left main coronary artery (LMCA). Panel B shows the M-mode echocardiogram of the LMCA.",
"    <div class=\"footnotes\">",
"     PV: pulmonary valve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6944=[""].join("\n");
var outline_f6_50_6944=null;
var title_f6_50_6945="Itopride: International drug information";
var content_f6_50_6945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Itopride: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ganaton (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2529476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Itopride Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2529477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Prokinetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2529478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of gastrointestinal symptoms caused by reduced gastrointestinal motility.",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2529480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 50 mg 3 times/day before meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2529481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10466 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6945=[""].join("\n");
var outline_f6_50_6945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369845\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529476\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529477\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529478\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529480\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821244\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529481\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10466\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10466|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_50_6946="Swollen hands early scleroderma";
var content_f6_50_6946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Swollen hands in early systemic sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swollen hands, which may mimic juvenile idiopathic arthritis, in a patient with early generalized scleroderma. These symptoms generally persist for a few weeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6946=[""].join("\n");
var outline_f6_50_6946=null;
var title_f6_50_6947="Ciprofloxacin (ophthalmic): Pediatric drug information";
var content_f6_50_6947=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/7/26740?source=see_link\">",
"    see \"Ciprofloxacin (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=see_link\">",
"    see \"Ciprofloxacin (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ciloxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9611240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ciloxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10586564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10586586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/7/26740?source=see_link\">",
"      see \"Ciprofloxacin (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;1 year and Adults: Solution: Instill 1-2 drops into the affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for the next 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment of corneal ulcers: Instill 2 drops every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day; on the second day, 2 drops every hour; then 2 drops every 4 hours thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;2 years and Adults: Ointment: Instill",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     \" ointment ribbon 3 times/day for 2 days, then twice daily for the next 5 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9611527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ciloxan&reg;: 3.33 mg/g (3.5 g) [equivalent to ciprofloxacin base 0.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 3.5 mg/mL (2.5 mL, 5 mL, 10 mL) [equivalent to ciprofloxacin base 0.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ciloxan&reg;: 3.5 mg/mL (5 mL) [contains benzalkonium chloride; equivalent to ciprofloxacin base 0.3%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9611242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes ointment",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10586587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only. Avoid contacting tip with skin or eye.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Instill ointment in the lower conjunctival sac.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10586584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from intense light; protect from freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10586565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of corneal ulcers and conjunctivitis due to susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3198568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ciprofloxacin may be confused with cephalexin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ciloxan&reg; may be confused with Cytoxan",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F13854755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Unpleasant taste (immediately after instillation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Conjunctival hyperemia, crystal formation, burning, discomfort, foreign body sensation, itching, keratopathy (ointment), lid margin crusting, white crystalline precipitate (solution; in superficial portion of corneal defect; reversible after completion of therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Corneal infiltrates, corneal staining, hypersensitivity reactions, keratitis, lid edema, nausea, photophobia, tearing, vision decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10586566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciprofloxacin, any component, or other quinolones",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9611335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9611268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9611269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. When administered orally or I.V., ciprofloxacin crosses the placenta. Refer to the Ciprofloxacin (Systemic) monograph for details. The amount of ciprofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral or I.V. doses.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10586585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-gyrase and topoisomerase I.V. in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10586588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=see_link\">",
"      see \"Ciprofloxacin (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remove contact lenses prior to administration.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15950 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6947=[""].join("\n");
var outline_f6_50_6947=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586564\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586586\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611527\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611242\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586587\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586584\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586565\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3198568\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854755\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586566\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299045\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611335\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611268\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611269\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586585\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586588\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_50_6948="Changes calcium sensitivity";
var content_f6_50_6948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Effects of interventions on the calcium sensitivity of the contractile apparatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A summarizes different interventions and their effects on myofilament calcium sensitivity. Panel B show the effects of these interventions on the intracellular calcium transient. Note that drugs that decrease myofilament calcium sensitivity increase the amplitude of the calcium transient relative to drugs that do not change or increase myofilament calcium sensitivity. Panel C shows the effects of these agents on the force (F",
"    <sub>",
"     max",
"    </sub>",
"    ) versus calcium concentration ([Ca",
"    <sup>",
"     2+",
"    </sup>",
"    ]",
"    <sub>",
"     o",
"    </sub>",
"    ) relationship of skinned or hyperpermeabilized fibers. The interventions that increase myofilament sensitivity to calcium have the potential to cause or exacerbate diastolic dysfunction; conversely, agents which decrease myofilament sensitivity to calcium have a potential lusitropic effect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6948=[""].join("\n");
var outline_f6_50_6948=null;
var title_f6_50_6949="Protein C concentrate: Drug information";
var content_f6_50_6949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Protein C concentrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/51/31540?source=see_link\">",
"    see \"Protein C concentrate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"    see \"Protein C concentrate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4594766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ceprotin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4594770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant;",
"     </li>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Enzyme;",
"     </li>",
"     <li>",
"      Protein C",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4595363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient variables (including age, clinical condition, and plasma levels of protein C) will influence dosing and duration of  therapy. Individualize dosing based on protein C activity and patient pharmacokinetic profile. Dosing is dependent on the severity of protein C deficiency, age of patient, clinical condition, and patient's level of protein C. The frequency, duration, and dose should be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Severe congenital protein C deficiency:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute episode/short-term prophylaxis: Initial dose: 100-120 units/kg (for determination of recovery and half-life)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Subsequent 3 doses: 60-80 units/kg every 6 hours (adjust to maintain peak protein C activity of 100%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dose: 45-60 units/kg every 6 or 12 hours (adjust to maintain recommended maintenance trough protein C activity levels &gt;25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Long-term prophylaxis: Maintenance dose: 45-60 units/kg every 12 hours (recommended maintenance trough protein C activity levels &gt;25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4595362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"      see \"Protein C concentrate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient variables (including age, clinical condition, and plasma levels of protein C) will influence dosing and duration of  therapy. Individualize dosing based on protein C activity and patient pharmacokinetic profile. Dosing is dependent on the severity of protein C deficiency, age of patient, clinical condition, and patient's level of protein C. The frequency, duration, and dose should be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Severe congenital protein C deficiency:",
"     </b>",
"     I.V. Refer to adult  dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4595369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ceprotin: ~500 units, ~1000 units [contains albumin (human), heparin (may have trace amounts), mouse protein (may have trace amounts), sodium; actual potency is printed on the vial label; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4594768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4595365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by intravenous injection at a rate not to exceed 2 mL/minute. In children &lt;10 kg, administration should not exceed a rate of 0.2 mL/kg/minute. Administration must be completed within 3 hours of solution preparation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4594771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement therapy for severe congenital protein C deficiency for the prevention and/or treatment of venous thromboembolism and purpura fulminans",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4594763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ceprotin may be confused with aprotinin, Cipro&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Protein C concentrate (human) may be confused with activated protein C (human, recombinant) which refers to drotrecogin alfa",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4595342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding may be associated with protein C administration. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents that alter hemostasis and patient susceptibility. Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reactions (itching and rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Fever, hemothorax, hypotension, hyperhidrosis, restlessness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4595337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to protein C or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4595338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heparin-induced thrombocytopenia (HIT): Trace amounts of heparin contained within the formulation may lead to HIT; evaluate platelet counts if HIT is suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Formulation may contain trace amounts of mouse protein and/or heparin. Discontinue use in the presence of hypersensitivity/allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution; not studied in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use caution; not studied in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticoagulants: An increase risk of bleeding may be seen in patients receiving concomitant anticoagulant therapy including thrombolytic agents, heparin, oral anticoagulants, glycoprotein IIb/IIIa antagonists, platelet aggregation inhibitors, and aspirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sodium-restricted patients: Use with caution in patients where sodium restriction is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infections: Product of human plasma; may potentially contain infectious agents which could transmit disease; screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces this risk. (Consideration should be given for patients to receive appropriate vaccinations during therapy [eg, hepatitis A or B vaccine].)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4595347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4595349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Recent use/intake of herbs with anticoagulant or antiplatelet activity (including cat's claw, feverfew, garlic, ginkgo, ginseng, and horse chestnut seed) may increase the risk of bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4595332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4595333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies have not been performed. It is unknown if administration during pregnancy will result in fetal harm.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4595335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4595336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in nursing mothers has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4595364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     At maximum daily doses, product formulation contains sodium &gt;200 mg.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ceprotin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $1.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $1.69",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4595367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protein C activity (chromogenic assay) prior to and during therapy; signs and symptoms of bleeding; hemoglobin/hematocrit, PT/INR, platelet count",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4595355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ceprotin (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Octaplex (BR, DK);",
"     </li>",
"     <li>",
"      Protexel (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4595353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Converted to activated protein C (APC). APC is a serine protease which inactivates factors Va and VIIIa, limiting thrombotic formation.",
"     <i>",
"      In vitro",
"     </i>",
"     data also suggest inhibition of plasminogen activator inhibitor-1 (PAF-1) resulting in profibrinolytic activity, inhibition of macrophage production of tumor necrosis factor, blocking of leukocyte adhesion, and limitation of thrombin-induced inflammatory responses.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4595356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.074L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Activated protein C (APC) inactivated by plasma protease inhibitors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Median: 9.8 hours; range 4.9-14.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: T",
"     <sub>",
"      max",
"     </sub>",
"     : 0.5 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10094 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6949=[""].join("\n");
var outline_f6_50_6949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594766\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594770\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595363\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595362\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595369\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594768\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595365\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594771\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594763\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595342\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595337\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595338\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299957\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595347\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595349\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595332\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595333\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595335\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595336\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595364\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324135\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595367\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595355\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539986\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595353\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595356\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10094|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/51/31540?source=related_link\">",
"      Protein C concentrate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=related_link\">",
"      Protein C concentrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_50_6950="Androgenetic alopecia bitemporal recession";
var content_f6_50_6950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bitemporal hair loss in a man with androgenetic alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6950=[""].join("\n");
var outline_f6_50_6950=null;
var title_f6_50_6951="Vitamin B3 (niacin): Drug information";
var content_f6_50_6951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin B3 (niacin): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/53/26452?source=see_link\">",
"    see \"Vitamin B3 (niacin): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/2/5158?source=see_link\">",
"    see \"Vitamin B3 (niacin): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Niacin-Time&reg; [OTC];",
"     </li>",
"     <li>",
"      Niacor&reg;;",
"     </li>",
"     <li>",
"      Niaspan&reg;;",
"     </li>",
"     <li>",
"      Slo-Niacin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Niaspan&reg;;",
"     </li>",
"     <li>",
"      Niaspan&reg; FCT;",
"     </li>",
"     <li>",
"      Niodan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Formulations of niacin (regular release versus extended release) are not interchangeable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowances",
"     </b>",
"     (National Academy of Sciences, 1998): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;19 years: Females: 14 mg/day; Males: 16 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnancy (all ages): 18 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactation (all ages): 17 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary supplement (OTC labeling):",
"     </b>",
"     Oral: 50 mg twice daily or 100 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Many over-the-counter formulations exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperlipidemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Regular release formulation (Niacor&reg;):",
"     </i>",
"     Initial: 250 mg once daily (with evening meal); increase frequency and/or dose every 4-7 days to desired response or first-level therapeutic dose (1.5-2 g/day in 2-3 divided doses); after 2 months, may increase at 2- to 4-week intervals to 3 g/day in 3 divided doses (maximum dose: 6 g/day [NCEP recommends 4.5 g/day] in 3 divided doses). Usual daily dose after titration (NCEP, 2002): 1.5-3 g/day.",
"     <b>",
"      Note:",
"     </b>",
"     Many over-the-counter formulations exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sustained release (or controlled release) formulations:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Several over-the-counter formulations exist. Usual daily dose after titration (NCEP, 2002): 1-2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release formulation (Niaspan&reg;):",
"     </i>",
"     Initial: 500 mg at bedtime for 4 weeks, then 1 g at bedtime for 4 weeks; adjust dose to response and tolerance; may increase dose every 4 weeks by 500 mg/day to a maximum of 2 g/day. Usual daily dose after titration (NCEP, 2002): 1-2 g once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If additional LDL-lowering is necessary with lovastatin or simvastatin: Recommended initial lovastatin or simvastatin dose: 20 mg/day (maximum lovastatin or simvastatin dose: 40 mg/day);",
"     <b>",
"      Note:",
"     </b>",
"     Lovastatin prescribing information recommends a maximum dose of 20 mg/day with concurrent use of niacin (&gt;1 g/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pellagra (unlabeled use):",
"     </b>",
"     Oral: 50-100 mg 3-4 times/day; maximum: 500 mg/day (some experts prefer niacinamide for treatment due to more favorable side effect profile)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/2/5158?source=see_link\">",
"      see \"Vitamin B3 (niacin): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Formulations of niacin (regular release versus extended release) are not interchangeable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake",
"     </b>",
"     (National Academy of Sciences, 1998): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0-5 months: 2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-11 months: 3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowances",
"     </b>",
"     (National Academy of Sciences, 1998): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 12 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: Females: 14 mg/day; Males: 16 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;19 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pellagra (unlabeled use)",
"     </b>",
"     Oral: 50-100 mg/dose 3 times/day (some experts prefer niacinamide for treatment due to more favorable side effect profile)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F200988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment recommended; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F200989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with significant or unexplained hepatic dysfunction, active liver disease or unexplained persistent transaminase elevations.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F5943170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hepatic toxicity: Transaminases rise &ge;3 times ULN, either persistent or if symptoms of nausea, fever, and/or malaise occur: Discontinue therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, timed release, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 50 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, timed release, oral: 250 mg, 400 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 100 mg, 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Niacor&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slo-Niacin&reg;: 250 mg, 500 mg, 750 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Niaspan&reg;: 500 mg, 750 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral: 250 mg, 500 mg, 750 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Niacin-Time&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niaspan&reg;: Administer at bedtime. Tablet strengths are not interchangeable. When switching from immediate release tablet, initiate Niaspan&reg; at lower dose and titrate. If therapy is interrupted for an extended period, dose should be retitrated. Long-acting forms should not be crushed, broken, or chewed. Do not substitute long-acting forms for immediate release ones.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of dyslipidemias (Fredrickson types IIa and IIb or primary hypercholesterolemia) as mono- or adjunctive therapy; to lower the risk of recurrent MI in patients with a history of MI and hyperlipidemia; to slow progression or promote regression of coronary artery disease; treatment of hypertriglyceridemia in patients at risk of pancreatitis; dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10149224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pellagra",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Niacin may be confused with Minocin&reg;, niacinamide, Niaspan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, atrial fibrillation, edema, flushing, hypotension, orthostasis, palpitation, syncope (rare), tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, headache, insomnia, migraine, nervousness, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acanthosis nigricans, burning skin, dry skin, hyperpigmentation, maculopapular rash, pruritus, rash, skin discoloration, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Glucose tolerance decreased, gout, phosphorous levels decreased, hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, amylase increased, diarrhea, dyspepsia, eructation, flatulence, nausea, peptic ulcers, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Platelet counts decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic necrosis (rare), hepatitis, jaundice, transaminases increased (dose-related), prothrombin time increased, total bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, leg cramps, myalgia, myasthenia, myopathy (with concurrent HMG-CoA reductase inhibitor), paresthesia, rhabdomyolysis (with concurrent HMG-CoA reductase inhibitor; rare), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cystoid macular edema, toxic amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions (rare; includes anaphylaxis, angioedema, laryngismus, vesiculobullous rash), LDH increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to niacin, niacinamide, or any component of the formulation; active hepatic disease or significant or unexplained persistent elevations in hepatic transaminases; active peptic ulcer; arterial hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flushing/pruritus: Flushing and pruritus, common adverse effects of niacin, may be attenuated with a gradual increase in dose, and/or by taking aspirin (adults: 325 mg) or an NSAID 30-60 minutes before dosing. Compliance is enhanced with twice-daily dosing (extended-release product excluded).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Cases of severe hepatotoxicity, including fulminant hepatic necrosis, have occurred when immediate release (crystalline) niacin products have been substituted with sustained-release (modified release, timed-release) niacin products at equivalent doses. Patients should be initiated with low doses (eg, 500 mg at bedtime) with titration to achieve desired response. Liver function tests should be monitored in all patients receiving lipid-lowering doses of niacin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with unstable angina or MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use niacin with caution in patients with diabetes mellitus; niacin may increase fasting blood glucose, although clinical data suggest increases are generally modest (&lt;5%). Monitor glucose; adjustment of hypoglycemic therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use with caution in patients with active gallbladder disease; can exacerbate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Use may be associated with hyperuricemia. Use with caution in patients with gout.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or heavy ethanol users: Use with caution in patients with a past history of hepatic impairment and/or who consume substantial amounts of ethanol; monitor liver function tests. Contraindicated with active liver disease or unexplained persistent transaminase elevation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: Use with caution in patients taking anticoagulants; may slightly increase prothrombin time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HMG-CoA reductase inhibitors: Rare cases of rhabdomyolysis have occurred during concomitant use with HMG-CoA reductase inhibitors; with concurrent use or if symptoms suggestive of myopathy occur, monitor creatine phosphokinase (CPK) and potassium. Use with caution in patients with renal impairment, inadequately treated hypothyroidism, patients with diabetes or the elderly; risk for myopathy and rhabdomyolysis may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability:",
"     <b>",
"      Note:",
"     </b>",
"     Formulations of niacin (regular release versus extended release) are not interchangeable; bioavailability varies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Prior to initiation, secondary causes for hypercholesterolemia (eg, poorly controlled diabetes mellitus, hypothyroidism) should be excluded; management with diet and other nonpharmacologic measures (eg, exercise or weight reduction) should be attempted prior to initiation. Use has not been evaluated in Fredrickson type I or III dyslipidemias.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2914257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Niacin may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.  Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F200979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid heavy use; avoid use around niacin dose.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5943163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water soluble vitamins cross the placenta. When used as a dietary supplement, niacin requirements may be increased in pregnant women compared to nonpregnant women (IOM, 1998). Animal reproduction studies have not been conducted. It is not known if niacin at lipid-lowering doses is harmful to the developing fetus. If a woman becomes pregnant while receiving niacin for primary hypercholesterolemia, niacin should be discontinued. If a woman becomes pregnant while receiving niacin for hypertriglyceridemia, the benefits and risks of continuing niacin should be assessed on an individual basis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/consider risk:benefit",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5943165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Niacin is excreted in human breast milk. When used as a dietary supplement, niacin requirements may be increased in nursing women compared to non-nursing women (IOM, 1998). Because lipid-lowering doses of niacin may cause serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F200971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with meal; low-fat meal if treating hyperlipidemia. Avoid hot drinks around the time of niacin dose.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F200970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Niacin ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $11.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Niacin ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $3.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $5.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $7.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (100): $8.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Niaspan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (90): $350.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (90): $500.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (90): $620.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Slo-Niacin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $9.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $13.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $18.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Niacin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $1.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $2.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $3.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $4.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Niacor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $38.03",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F200960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose (in diabetic patients); CPK and serum potassium (if on concurrent HMG-CoA reductase inhibitor); liver function tests pretreatment, every 6-12 weeks for first year, then periodically (approximately every 6 months), monitor liver function more frequently if history of transaminase elevation with prior use; lipid profile; platelets; PT (if on anticoagulants); uric acid (if predisposed to gout); phosphorus (if predisposed to hypophosphatemia)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acido Nicotinico (CO);",
"     </li>",
"     <li>",
"      Acidum nicotinicum (HU);",
"     </li>",
"     <li>",
"      Apo-Nicotinic Acid (NZ);",
"     </li>",
"     <li>",
"      Exlip ER (KP);",
"     </li>",
"     <li>",
"      Niacyn (PL);",
"     </li>",
"     <li>",
"      Niaspan (CH, CL, DE, FI, GB, HK, IE, NL, PT, SE, TH);",
"     </li>",
"     <li>",
"      Niaspan LP (FR);",
"     </li>",
"     <li>",
"      Nicangin (NO);",
"     </li>",
"     <li>",
"      Nicobid (HK);",
"     </li>",
"     <li>",
"      Nicotabs (TH);",
"     </li>",
"     <li>",
"      Nicotinic Acid (AU);",
"     </li>",
"     <li>",
"      Nyclin (TW);",
"     </li>",
"     <li>",
"      Pepevit (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Component of two coenzymes which is necessary for tissue respiration, lipid metabolism, and glycogenolysis; inhibits the synthesis of very low density lipoproteins (VLDL) and low density lipoproteins (LDL); may also increase the rate of chylomicron triglyceride removal from plasma.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and extensive (60% to 76%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Mainly to hepatic, renal, and adipose tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass effects; converted to nicotinamide adenine dinucleotide, nicotinuric acid, and other metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release formulation: 30-60 minutes; extended release formulation: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine 60% to 88% (unchanged drug [up to 12% recovered after multiple dosing] and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carlson LA and Rosenhamer G, &ldquo;Reduction of Mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by Combined Treatment With Clofibrate and Nicotinic Acid,&rdquo;",
"      <i>",
"       Acta Med Scand",
"      </i>",
"      , 1988, 223(5):405-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/3287837/pubmed\" id=\"3287837\" target=\"_blank\">",
"        3287837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Clofibrate and Niacin in Coronary Heart Disease,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1975, 231(4):360-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/1088963/pubmed\" id=\"1088963\" target=\"_blank\">",
"        1088963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elam MB, Hunninghake DB, Davis KB, et al, &ldquo;Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease - Study: A Randomized Trial. Arterial Disease Multiple Intervention Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 284(10):1263-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/10979113/pubmed\" id=\"10979113\" target=\"_blank\">",
"        10979113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegyi J, Schwartz RA, and Hegyi V, &ldquo;Pellagra: Dermatitis, Dementia, and Diarrhea,&rdquo;",
"      <i>",
"       Int J Dermatol",
"      </i>",
"      , 2004, 43(1):1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/14693013/pubmed\" id=\"14693013\" target=\"_blank\">",
"        14693013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      </i>",
"      <sub>",
"       6",
"      </sub>",
"      <i>",
"       , Folate, Vitamin B",
"      </i>",
"      <sub>",
"       12",
"      </sub>",
"      <i>",
"       , Pantothenic Acid, Biotin and Choline",
"      </i>",
"      , Washington, DC: National Academy Press, 1998.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knopp RH, Ginsberg J, Albers JJ, et al, &ldquo;Contrasting Effects of Unmodified and Time-Release Forms of Niacin on Lipoproteins in Hyperlipidemic Subjects: Clues to Mechanism of Action of Niacin,&rdquo;",
"      <i>",
"       Metabolism",
"      </i>",
"      , 1985, 34(7):642-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/3925290/pubmed\" id=\"3925290\" target=\"_blank\">",
"        3925290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahley RW and Bersot TP, &ldquo;Drug Therapy for Hypercholesterolemia and Dyslipidemia,&rdquo;",
"      <i>",
"       Goodman and Gilman's The Pharmacological Basis of Therapeutics",
"      </i>",
"      , 10th ed, Hardman JE and Limbird LE, eds, New York, NY: McGraw-Hill, 2001, 993-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKenney JM, Proctor JD, Harris S, et al, &ldquo;A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1994, 271(9):672-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/8309029/pubmed\" id=\"8309029\" target=\"_blank\">",
"        8309029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mills E, Prousky J, Raskin G, et al, &ldquo;The Safety of Over-the-counter Niacin. A Randomized Placebo-Controlled Trial [ISRCTNI8054903],&rdquo;",
"      <i>",
"       BMC Clin Pharmacol",
"      </i>",
"      , 2003, 3:4-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/14614780/pubmed\" id=\"14614780\" target=\"_blank\">",
"        14614780",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor AJ, Sullenberger LE, Lee JH, et al, &ldquo;Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2: A Double-blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(23):3512-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/15537681/pubmed\" id=\"15537681\" target=\"_blank\">",
"        15537681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Final Report,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 106(25):3143-421.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/50/6951/abstract-text/12485966/pubmed\" id=\"12485966\" target=\"_blank\">",
"        12485966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9695 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6951=[""].join("\n");
var outline_f6_50_6951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201008\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200986\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200999\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200987\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200988\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200989\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5943170\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200962\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200948\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200965\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200963\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149224\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201016\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201006\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200968\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200952\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299759\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2914257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200979\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200958\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5943163\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200993\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5943165\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200971\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200970\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200960\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200972\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200951\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200967\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9695\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9695|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/53/26452?source=related_link\">",
"      Vitamin B3 (niacin): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/2/5158?source=related_link\">",
"      Vitamin B3 (niacin): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_50_6952="Lumbosacral plexus";
var content_f6_50_6952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Anatomy of the lumbosacral plexus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6952=[""].join("\n");
var outline_f6_50_6952=null;
var title_f6_50_6953="Complementary and alternative therapies for allergic rhinitis and conjunctivitis";
var content_f6_50_6953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complementary and alternative therapies for allergic rhinitis and conjunctivitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/50/6953/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/50/6953/contributors\">",
"     Leonard Bielory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/50/6953/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/50/6953/contributors\">",
"     Jonathan Corren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/50/6953/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/50/6953/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/50/6953/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26306525\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary and alternative medicine (CAM) therapies for allergic rhinitis and conjunctivitis include Chinese herbal medicine (CHM), Ayurvedic medicine, other single and multiple herb preparations, acupuncture, homeopathy, and several other modalities. CAM therapies continue to gain popularity in the United States and throughout the world for the treatment of asthma and allergies.",
"   </p>",
"   <p>",
"    CAM therapies for allergic",
"    <span class=\"nowrap\">",
"     rhinitis/conjunctivitis",
"    </span>",
"    are discussed in this topic review. Chinese herbal medicine for allergic diseases, and CAM therapies for asthma are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=see_link\">",
"     \"Chinese herbal medicine for the treatment of allergic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link\">",
"     \"Alternative and experimental agents for the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4356386\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary and alternative medicine (CAM) is commonly defined as a group of diverse medical and health care systems, practices, and products that are not generally considered part of the conventional allopathic medical practices. Complementary therapies are used together with conventional allopathic medicine, while alternative therapies are used in place of conventional medicine. More general reviews of the principles of various CAM therapies are also found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=see_link\">",
"     \"Overview of complementary and alternative medicine in pediatrics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"     \"Acupuncture\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26903?source=see_link\">",
"     \"Homeopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than 20 percent of the United States population appears to suffer from an atopic disorder, such as asthma, allergic rhinitis, and atopic dermatitis, and over 42 percent of people (both adults and children) have used CAM for their atopic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The popularity of CAM therapies for allergic disease is even greater in some European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, it is important to ask patients about the use of CAM therapies in a nonjudgmental manner.",
"   </p>",
"   <p>",
"    The use of CAM is growing in Western countries because of the reputed effectiveness, low cost, and favorable safety profiles of some therapies. Patients are often interested in alternative therapy either because conventional therapies are unsatisfactory or because of concerns about side effects of synthetic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The chronic nature of allergic diseases and the paucity of preventive or curative treatments also stimulate interest in CAM therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21282295\">",
"    <span class=\"h2\">",
"     Barriers to integration with allopathic medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major concerns with CAM is that it is perceived to be natural and safe by patients, but as reflected in a study in 2009 that examined the safety reporting of CAM in randomized controlled trials, reporting of adverse effects was largely inadequate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/8\">",
"     8",
"    </a>",
"    ]. Improvement in safety reporting would facilitate integration into routine patient care. However, until this materializes, health care providers can familiarize themselves as much as possible with the available scientific literature on CAM. Evidence-based information of CAM therapies is available through several internet sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of herbal medicine and dietary supplements\", section on 'Internet evidence-based resources'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the high prevalence of allergic diseases and associated costs of the CAM treatments, high quality data about these therapies are needed so that practice guidelines can be established. In the United States, the National Center for Complementary and Alternative Medicine (NCCAM) (",
"    <a class=\"external\" href=\"file://www.nccam.nih.gov/\">",
"     www.nccam.nih.gov",
"    </a>",
"    ) has been tasked with evaluating mechanisms, efficacy, and safety of botanical medicines through basic science studies, clinical research, and the establishment of dedicated botanical research centers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The design of randomized placebo-controlled studies in CAM is complicated by difficulties in blinding, creating an appropriate placebo (particularly for acupuncture), and designing a control treatment when the mechanisms of actions of the modality in question are poorly delineated (such as homeopathy). Additionally, the difference in philosophy of CAM interventions from conventional health care allows for significant variation in the way CAM modalities are practiced (ie, therapies are often individualized for a particular patient and their specific disease state). Finally, the efficacy of CAM therapies may be heavily influenced by the patient&rsquo;s perception of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    interaction with the provider, which is often more personal than the interaction between patients and allopathic health care providers. Thus, results may vary significantly among CAM providers, and studies of CAM must also account for the influence of the patient-provider relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4357371\">",
"    <span class=\"h1\">",
"     SPECIFIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;This review is limited to those therapies about which there is published literature specifically concerning the treatment of allergic",
"    <span class=\"nowrap\">",
"     rhinitis/conjunctivitis.",
"    </span>",
"    These therapies include traditional Chinese medicine, acupuncture, Ayurvedic medicine, a variety of herbal therapies, and several others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21282386\">",
"    <span class=\"h2\">",
"     Traditional Chinese medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional Chinese medicine (TCM) includes herbal therapy, acupuncture, massage, and dietary therapy. These practices originated in China and have been used in East Asia for centuries as a part of mainstream medical care. TCM treatments for allergic rhinitis and conjunctivitis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=see_link&amp;anchor=H15105480#H15105480\">",
"     \"Chinese herbal medicine for the treatment of allergic diseases\", section on 'Therapy for allergic rhinitis and conjunctivitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15106287\">",
"    <span class=\"h2\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture is a component of traditional Chinese medicine that was originally thought to work on the principle of redistribution of Qi, the life energy. In traditional Chinese medicine, disease is believed to originate from an imbalance of Qi or poor flow of Qi. The difficulties in designing trials of acupuncture are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link&amp;anchor=H6#H6\">",
"     \"Acupuncture\", section on 'Basic theory'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link&amp;anchor=H19#H19\">",
"     \"Acupuncture\", section on 'Difficulties in research'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of acupuncture for the treatment of allergic rhinitis have shown mixed results, with the most rigorous studies showing very modest clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review identified 116 potentially relevant articles, of which 12 met criteria for inclusion by studying needle acupuncture, examining clinically relevant outcomes, and including a control, sham, or comparator treatment group [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/10\">",
"       10",
"      </a>",
"      ]. The results were different for seasonal and perennial allergic rhinitis. There were no effects on seasonal symptoms, although some benefit was apparent for perennial symptoms. The magnitude of effect could not be estimated, although drug therapy could not be reduced as a result of acupuncture in either type of rhinitis.",
"     </li>",
"     <li>",
"      A subsequent randomized controlled trial demonstrated statistically significant, but clinically modest improvement in the primary endpoint of total nasal symptom score after the fourth week of treatment. Improvement was not sustained one week after completion of the four-week course, but was surprisingly present three weeks later [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another randomized trial of 422 patients with seasonal allergic rhinitis to birch and grass pollen, subjects were treated with eight weeks of acupuncture with rescue medication (RM), sham acupuncture with RM, or RM alone [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/12\">",
"       12",
"      </a>",
"      ]. Rhinitis-related quality of life and antihistamine use were measured after the eight weeks of treatment, an additional eight weeks later, and one year later. When compared with sham acupuncture with RM and RM alone, acupuncture with RM resulted in an improvement of 0.5 points and a reduction in medication use of 0.7 points, where 1 point was equivalent to taking one less 10 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      tablet daily. Thus, the benefit was statistically significant, but of questionable clinical importance. Possible technical issues with the protocol included the use of more needles in the acupuncture patients versus the sham patients (16 compared with 10) and a larger fraction of patients in the acupuncture arm having high expectations for acupuncture efficacy at baseline (85 versus 73 percent). In addition, the study was performed in two centers in South Korea and China, and pollen counts during the years of treatment and observation, which can dramatically influence results, were not reported. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link&amp;anchor=H1231910994#H1231910994\">",
"       \"Acupuncture\", section on 'Trials for conditions other than pain'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the best trials of acupuncture for allergic rhinitis support limited benefit. Despite this, acupuncture may be a reasonable option for interested patients with relatively mild disease who wish to minimize medication use and find the cost of therapy acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14493471\">",
"    <span class=\"h2\">",
"     Ayurveda",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ayurvedic medicine is a medical tradition originating from India and derived from the teachings of ancient Hindu healers, which first appeared in text between 1500 and 1000 BC. Like traditional Chinese medicine, Ayurvedic therapeutic interventions include yoga, meditation, breathing exercises, and herbal preparations. In its truest form, Ayurveda exists for the &ldquo;promotion of health&rdquo; rather than the treatment of specific disease states that have already begun to affect the body.",
"   </p>",
"   <p>",
"    Ayurvedic herbal therapies have been evaluated in the treatment of allergic rhinitis. Aller-7 is a mixture of seven Indian herbs (Albizia lebbeck, Terminalia chebula, Terminalia bellerica, Phyllanthus emblica, Piper nigrum, Piper longum, and Zingiber officinale) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/16\">",
"     16",
"    </a>",
"    ]. In vitro studies examining the mixture demonstrated antihistaminic and antiinflammatory properties. In an experimental model using the nonspecific mast cell degranulating agent",
"    <span class=\"nowrap\">",
"     48/80",
"    </span>",
"    (&ldquo;antihistamine model&rdquo;), Aller-7 appeared to be equivalent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    . In the best human study to date, Aller-7 was compared with placebo in 545 adult patients with allergic rhinitis (171 of whom took part in randomized protocols, while the others were treated in an open-label fashion, treated for 12 weeks with 660 mg Aller-7 twice daily by mouth) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/17\">",
"     17",
"    </a>",
"    ]. Clinically-significant effects were noted at 6 and 12 weeks, which included 10 to 20 percent improvement in congestion, rhinorrhea, and sneezing compared with the placebo group in those patients in randomized protocols. Adverse effects were almost twice that of placebo and were largely mild gastrointestinal issues (eg, gastritis, discomfort, dryness of mouth). Aller-7 is commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26306590\">",
"    <span class=\"h2\">",
"     Herbal therapies (systemic)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of herbal preparations may be used by patients with allergic rhinitis and conjunctivitis, although scientific evaluation of herbal products has been limited and only those that have been evaluated in published clinical trials are reviewed here. A 2007 systematic review identified 16 randomized controlled trials (RCTs) that met eligibility criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/18\">",
"     18",
"    </a>",
"    ]. The agents discussed in this section are listed by their English names and their Latin or pharmacopeial names.",
"   </p>",
"   <p>",
"    Most herbal preparations contain several components; each with potentially varying physiologic and pharmacologic properties. However, herbal therapies that differ by name may contain identical components and thus share similar clinical effects and adverse effects. This is important when trying to analyze studies that attribute a clinical or physiologic property to a specific herbal preparation.",
"   </p>",
"   <p>",
"    In many countries, herbal medicines are minimally regulated and uncommonly monitored for adverse events by national surveillance systems. However, the increasing popularity of herbal medicines has led to concerns over their safety, quality, and efficacy on the part of health authorities and the general public. In response to these concerns, the World Health Organization has published formal monographs on selected medicinal plants to establish quality standards of herbal products and outline the parameters for their safe and effective use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/19\">",
"     19",
"    </a>",
"    ]. Safety issues surrounding the use of herbal medications are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=see_link\">",
"     \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7646786\">",
"    <span class=\"h3\">",
"     Choice of brand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who use herbs often ask their providers what brand should be used. Lack of regulatory reform in the herbal industry makes it difficult for the clinician to provide an informed response. One option is to recommend brands that have been tested by independent sources, such as Consumer Labs, and found to meet minimum quality criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/20\">",
"     20",
"    </a>",
"    ]. For ethical reasons, supplements sold through practitioners' offices or multilevel marketing plans should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7646793\">",
"    <span class=\"h3\">",
"     Children and pregnant or lactating women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very few studies of herbal therapies have been conducted on infants and children or in pregnant and lactating women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/21\">",
"     21",
"    </a>",
"    ]. Issues of particular concern include proper dosing in young children and greater susceptibility of fetuses and children to potential contaminants. We therefore discourage the use of herbal therapies in these patient groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4358379\">",
"    <span class=\"h3\">",
"     Butterbur (Petasites hybridus)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracts from the root of butterbur (",
"    <em>",
"     Petasites hybridus",
"    </em>",
"    ) contain petasins, compounds that are believed to possess medicinal properties, possibly by altering the leukotriene pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/22\">",
"     22",
"    </a>",
"    ]. A systematic review of small, but randomized trials comparing herbal therapies with either placebo or active drug found evidence of efficacy based upon six double-blind randomized controlled trials (DBRCTs) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/18\">",
"     18",
"    </a>",
"    ]. In three of these, butterbur compared favorably with standard doses of nonsedating antihistamines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    , 10 mg daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    , 180 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Butterbur preparations are available under a variety of brand names.",
"   </p>",
"   <p>",
"    Multiple portions of the butterbur plant can contain pyrrolizidine alkaloids, compounds that have hepatotoxic and potentially mutagenic and carcinogenic effects in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. At least 40 reports have appeared worldwide concerning hepatotoxicity with use of butterbur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/28\">",
"     28",
"    </a>",
"    ]. Most cases of pyrrolizidine alkaloid toxicity result in moderate to severe liver damage. Early signs and symptoms include nausea and acute upper abdominal pain, while more advanced toxicity may present with abdominal distension, jaundice, and the development of ascites. In some cases, if the ingestion of the source is not stopped, the toxicity can lead to hepatic fibrosis and potentially fatal cirrhosis. Manufacturing processes can reduce the content of alkaloids, and consumers should choose products that are labeled as low in pyrrolizidine alkaloids. However, they should also be aware of this potential hazard and be advised about early symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4358409\">",
"    <span class=\"h3\">",
"     Tinofend (Tinospora cordifolia)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinofend is an Indian herbal medication containing extract from the stem of Tinospora cordifolia. In a double-blind randomized trial of 75 patients with allergic rhinitis, those receiving T. cordifolia (at a dose of 300 mg three times daily for eight weeks) reported statistically significant improvement in sneezing, nasal discharge, nasal obstruction, and nasal pruritus, compared with those receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/29\">",
"     29",
"    </a>",
"    ]. The drug was well tolerated, although it caused an increase in total blood leukocyte count in 70 percent of patients in the active treatment group, compared with 11 percent of those receiving placebo; a statistically significant difference. This was attributed to a possible &ldquo;immunostimulatory&rdquo; effect by the authors. There have been limited reports of hepatic toxicity, although several in vitro analyses performed by a manufacturer were reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12555896\">",
"    <span class=\"h3\">",
"     Cinnamon bark, Spanish needle, and acerola",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of Cinnamon bark extract, dehydrated Spanish Needle (Bidens pilosa) leaf and stem, and acerola fruit concentrate (at a dose of 450 mg three times daily) was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    (10 mg once daily) and placebo in a randomized, double-blind, crossover study of 20 subjects with allergic rhinitis and sensitization to timothy grass pollen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/32\">",
"     32",
"    </a>",
"    ]. Subjects took each study medication for two days and then underwent a nasal allergen challenge procedure with timothy pollen, after which nasal symptoms were assessed and nasal lavage fluid was examined for allergic mediators. Only loratadine significantly reduced symptoms acutely during the challenge, although both the botanical product and loratadine significantly reduced nasal symptoms two to eight hours after the challenge, compared with placebo. The magnitude of effect with both treatments was clinically significant. The botanical product appears to inhibit the production of prostaglandin D2 following challenge, which may suggest a steroid-like impact that affects the late-phase response of allergic inflammation. This product is commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7646030\">",
"    <span class=\"h3\">",
"     Ayurvedic herbal mixes",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are discussed above. (See",
"    <a class=\"local\" href=\"#H14493471\">",
"     'Ayurveda'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11050428\">",
"    <span class=\"h2\">",
"     Nasal sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal sprays containing either dilute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    or inert cellulose have demonstrated efficacy in randomized controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1144540401\">",
"    <span class=\"h3\">",
"     Capsaicin (Capsicum annum)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    , derived from red peppers, is believed to act in other forms of rhinitis by desensitizing nasal nerve fibers and reducing nasal hyperresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/34\">",
"     34",
"    </a>",
"    ]. In a randomized study of 42 patients with allergic and nonallergic rhinitis, an intranasal solution of capsaicin and eucalyptol (added to reduce the burning sensation that some patient experience with capsaicin) used twice a day for two weeks was compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/35\">",
"     35",
"    </a>",
"    ]. There was a statistically greater reduction in total nasal symptom score, with the greatest improvement in nasal congestion, sinus pain and pressure, and headache, while the reduction in sneezing, rhinorrhea, and post-nasal drip did not differ between the active and placebo groups. This product is commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15109033\">",
"    <span class=\"h3\">",
"     Cellulose powder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intranasal application of inert, micronized cellulose powder has been proposed to block mucosal allergen absorption. Some products suggest application every three hours. Products are available in many countries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/37\">",
"     37",
"    </a>",
"    ]. Some efficacy has been demonstrated in a small number of randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. The largest included 53 children (ages 8 to 18 years) with birch pollen allergic rhinitis who were randomized to cellulose powder or a control preparation of lactose powder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/40\">",
"     40",
"    </a>",
"    ]. Subjects were monitored for symptoms throughout the birch pollen season of one year. There was a significant reduction in total symptom scores from the nose and specifically for rhinorrhea, without adverse effects.",
"   </p>",
"   <p>",
"    Cellulose nasal powders have been available for nearly 20 years in some countries (United Kingdom). As far as the author and editors are aware, there are no reports of adverse effects with prolonged use. It seems logical that these products would interfere with the absorption of other nasal sprays used to treat allergic rhinitis, so if symptom control worsens on the combination, then the combination should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7622228\">",
"    <span class=\"h2\">",
"     CAM therapies with minimal evidence of efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other herbal preparations, homeopathic products, and miscellaneous therapies have been suggested for the treatment of allergic rhinitis or conjunctivitis. However, studies have either been of low quality or failed to show benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7645543\">",
"    <span class=\"h3\">",
"     Homeopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homeopathy works on the principle of treatment with &ldquo;similars&rdquo;. The remedies prescribed by homeopathic practitioners are essentially extremely dilute solutions of drugs known to cause the very symptoms that are to be treated. However, some products labeled as homeopathic can, in fact, contain substantial amounts of active ingredients and therefore could cause side effects and drug interactions.",
"   </p>",
"   <p>",
"    According to the literature reviewed, 3 to 4 percent of CAM users use homeopathy, and about 75 percent of patients seen by a homeopathic practitioners report symptomatic improvement. However, meta-analyses and systematic reviews have repeatedly concluded that homeopathy is not different from placebo in the treatment of any medical disorder, including allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26903?source=see_link\">",
"     \"Homeopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7646980\">",
"    <span class=\"h3\">",
"     Other herbal preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other herbal preparations, for which evidence of efficacy for allergic",
"    <span class=\"nowrap\">",
"     rhinitis/conjunctivitis",
"    </span>",
"    is limited or lacking, include quercetin, stinging nettle, Perilla frutescens, Gingko, milk thistle, and grape seed extract.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Quercetin",
"      </strong>",
"      &mdash; Bioflavonoids, such as quercetin, have been of interest in the treatment of allergic diseases based upon studies showing that these compounds could act as mast cell stabilizing agents, inhibiting the release of histamine, IL-8, and tumor necrosis factor (TNF), and inhibiting the formation of prostaglandin D2 in a dose-dependent fashion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/43\">",
"       43",
"      </a>",
"      ]. Quercetin is one of the components of an Artemisia abrotanum intranasal spray that was administered to 12 patients with allergic rhinitis, conjunctivitis, or asthma in a small uncontrolled study [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/44\">",
"       44",
"      </a>",
"      ]. All subjects reported improvement in symptoms within five minutes of application, which lasted several hours. Ocular symptoms also improved with intranasal application. Quercetin is also found in Spanish Needle. (See",
"      <a class=\"local\" href=\"#H12555896\">",
"       'Cinnamon bark, Spanish needle, and acerola'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Stinging nettle (Urtica dioica)",
"      </strong>",
"      &mdash; Extracts from the root and leaves of stinging nettle (Radix urticae) have been used to treat allergic rhinitis. A very small clinical effect was noted in one randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/45\">",
"       45",
"      </a>",
"      ]. The Latin genus name comes from the term &ldquo;burn&rdquo; due to the urticate (stinging) nature of its hairs secondary to the content histamine and other pruritogenic compounds.",
"      <br/>",
"      <br/>",
"      Stinging nettle has no known contraindications or drug interactions, although contact with fresh leaves causes allergic type reactions, such as urticaria and burning and itching upon application to mucosal surfaces, and ingestion is known to cause mild gastrointestinal disturbances and rare diarrhea. It is also used homeopathically. (See",
"      <a class=\"local\" href=\"#H7645543\">",
"       'Homeopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Perilla frutescens",
"      </strong>",
"      <em>",
"       &mdash;",
"      </em>",
"      Perilla frutescens is an Asian herb. Two doses of a preparation enriched for rosmarinic acid was compared with placebo in a RCT of 29 patients with seasonal allergic rhinoconjunctivitis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/46\">",
"       46",
"      </a>",
"      ]. A significant difference was seen in quality of life between the higher dose P. frutescens and placebo after three weeks of treatment, although specific nasal and ocular symptoms were not statistically different.",
"     </li>",
"     <li>",
"      <strong>",
"       Eucalyptus",
"      </strong>",
"      &mdash; The steam distillation of eucalyptus leaves generates an oil rich in 1,8-cineole. A clinical study showed that five minutes of inhalation resulted in the sensation of cooling and increased nasal airflow [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/47\">",
"       47",
"      </a>",
"      ]. Eucalyptus preparations have been studied as a nasal decongestant during acute infectious rhinitis when applied in conjunction with camphor, menthol, or steam [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Gingko biloba",
"      </strong>",
"      &mdash; There are limited studies in support of the treatment of allergic rhinitis and conjunctivitis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/49,50\">",
"       49,50",
"      </a>",
"      ] using solutions of gingko biloba extract, although one study did reflect a positive trend for the treatment of allergic conjunctivitis when applying the extract topically [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Milk thistle",
"      </strong>",
"      &mdash; Silybum marianum, or silymarin, is a compound extracted from milk thistle. It has antioxidant and antifibrotic properties and has been most extensively studied in the treatment of liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/51\">",
"       51",
"      </a>",
"      ]. One study showed that subjects with allergic rhinitis treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      , who also took silymarin, had reduced symptoms compared with those taking antihistamine alone [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/52\">",
"       52",
"      </a>",
"      ]. However, this herbal agent has been known to inhibit cytochrome P450 2C8 and 2C9, and alterations in drug levels are of a major concern as it has been shown to decrease the trough concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. It is not recommended for the treatment of allergic rhinitis at this time.",
"     </li>",
"     <li>",
"      <strong>",
"       Grape seed",
"      </strong>",
"      <strong>",
"       extract",
"      </strong>",
"      &mdash; Grape seed extract has antioxidant properties and is marketed for the treatment of a variety of illnesses. However, a placebo-controlled study did not demonstrate any positive effect of grape seed extract on the treatment of allergic rhinitis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7645328\">",
"    <span class=\"h3\">",
"     Laser therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser therapies deliver light energy to specific targets, including endobronchial tissues, tympanic membranes, blood, and skin. Laser therapy is described with various terms in the literature, including laser ablation, photodynamic therapy (PDT) of bronchial tissue, endobronchial helium-neon laser irradiation (ELI), and laseropuncture (laser acupuncture) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/56-63\">",
"     56-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no controlled trials of laser therapies for the treatment of allergic rhinitis. An uncontrolled series described 42 patients with refractory rhinitis (allergic and nonallergic) who were treated with a single treatment with a diode laser under local anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/64\">",
"     64",
"    </a>",
"    ]. Twenty-five reported subjective improvement in nasal symptomatology, especially nasal",
"    <span class=\"nowrap\">",
"     congestion/obstruction,",
"    </span>",
"    and positive effects on quality of life, up to six years later. Nonallergic rhinitis has also been treated with laser therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6953/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7644800\">",
"    <span class=\"h3\">",
"     Other types of treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other CAM therapies have been studied in respiratory or inflammatory diseases, but not specifically in allergic rhinitis. These include apitherapy (ie, bee sting therapy), behavior modification techniques, and speleo- or halotherapy (ie, cave air therapy and salt inhalation therapy, respectively). Thus, these are not discussed further.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=see_link\">",
"       \"Patient information: Alternative medicine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4359033\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is prudent to ask patients about the use of complementary and alternative medicine (CAM) in a nonjudgmental manner because a significant percentage of patients have tried or are actively using these therapies to treat allergic disorders. A paucity of well-designed studies makes it difficult for clinicians to recommend CAM therapies with confidence. However, patients who do wish to pursue CAM should consider the financial costs (which may be substantial) and be aware that long-term safety data on most of these therapies are lacking. (See",
"      <a class=\"local\" href=\"#H4356386\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional Chinese medicine (TCM) includes herbal therapy, acupuncture, massage, and dietary therapy. The use of TCM for allergic rhinitis is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=see_link&amp;anchor=H15105480#H15105480\">",
"       \"Chinese herbal medicine for the treatment of allergic diseases\", section on 'Therapy for allergic rhinitis and conjunctivitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies of acupuncture for the treatment of allergic rhinitis have shown modest benefit, although it is difficult to estimate the size of the effect in most positive studies. (See",
"      <a class=\"local\" href=\"#H15106287\">",
"       'Acupuncture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several herbal therapies that have demonstrated efficacy, including Ayurvedic mixes, butterbur, and Tinofend. Patients interested in these therapies should become familiar with the reported side effects and understand that these products are not systematically monitored for safety by drug regulatory bodies. We suggest that pregnant and nursing patients be advised to avoid herbal therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26306590\">",
"       'Herbal therapies (systemic)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who seek advice about what brand of herbal medicine to use can be referred to independent sources such as Consumer Labs, which tests various brands of herbal therapies for content and quality. (See",
"      <a class=\"local\" href=\"#H7646786\">",
"       'Choice of brand'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasal sprays consisting of dilute solutions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      or inert, micronized cellulose powder have shown efficacy for allergic rhinitis in randomized trials when administered several times daily. (See",
"      <a class=\"local\" href=\"#H11050428\">",
"       'Nasal sprays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of other herbal preparations, homeopathic products, and miscellaneous therapies have been suggested for the treatment of allergic rhinitis or conjunctivitis. However, studies have either been of low quality or failed to show benefit. (See",
"      <a class=\"local\" href=\"#H7622228\">",
"       'CAM therapies with minimal evidence of efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/1\">",
"      Kapoor S, Bielory L. Allergic rhinoconjunctivitis: complementary treatments for the 21st century. Curr Allergy Asthma Rep 2009; 9:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/2\">",
"      Kemper KJ, Vohra S, Walls R, et al. American Academy of Pediatrics. The use of complementary and alternative medicine in pediatrics. Pediatrics 2008; 122:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/3\">",
"      Sch&auml;fer T. Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. Ann Allergy Asthma Immunol 2004; 93:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/4\">",
"      Heimall J, Bielory L. Defining complementary and alternative medicine in allergies and asthma: benefits and risks. Clin Rev Allergy Immunol 2004; 27:93.",
"     </a>",
"    </li>",
"    <li>",
"     Heimall J, Bielory L. Complementary and alternative therapy in treatment of allergic diseases. In: Allergy, Mahmoudi M (Ed), McGraw-Hill/Medical Publishing Division, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/6\">",
"      Mainardi T, Kapoor S, Bielory L. Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin Immunol 2009; 123:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/7\">",
"      Li XM, Brown L. Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol 2009; 123:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/8\">",
"      Turner LA, Singh K, Garritty C, et al. An evaluation of the completeness of safety reporting in reports of complementary and alternative medicine trials. BMC Complement Altern Med 2011; 11:67.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Complementary and Alternative Medicine. Expanding Horizons of Health Care: Strategic Plan 2005-2009. NIH publication no. 04-5568., National Center for Complementary and Alternative Medicine; NIH, Bethesda, MD 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/10\">",
"      Lee MS, Pittler MH, Shin BC, et al. Acupuncture for allergic rhinitis: a systematic review. Ann Allergy Asthma Immunol 2009; 102:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/11\">",
"      Choi SM, Park JE, Li SS, et al. A multicenter, randomized, controlled trial testing the effects of acupuncture on allergic rhinitis. Allergy 2013; 68:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/12\">",
"      Brinkhaus B, Ortiz M, Witt CM, et al. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med 2013; 158:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/13\">",
"      Xue CC, An X, Cheung TP, et al. Acupuncture for persistent allergic rhinitis: a randomised, sham-controlled trial. Med J Aust 2007; 187:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/14\">",
"      Ng DK, Chow PY, Ming SP, et al. A double-blind, randomized, placebo-controlled trial of acupuncture for the treatment of childhood persistent allergic rhinitis. Pediatrics 2004; 114:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/15\">",
"      Brinkhaus B, Witt CM, Jena S, et al. Acupuncture in patients with allergic rhinitis: a pragmatic randomized trial. Ann Allergy Asthma Immunol 2008; 101:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/16\">",
"      Amit A, Saxena VS, Pratibha N, et al. Mast cell stabilization, lipoxygenase inhibition, hyaluronidase inhibition, antihistaminic and antispasmodic activities of Aller-7, a novel botanical formulation for allergic rhinitis. Drugs Exp Clin Res 2003; 29:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/17\">",
"      Saxena VS, Venkateshwarlu K, Nadig P, et al. Multicenter clinical trials on a novel polyherbal formulation in allergic rhinitis. Int J Clin Pharmacol Res 2004; 24:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/18\">",
"      Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of allergic rhinitis: a systematic review. Ann Allergy Asthma Immunol 2007; 99:483.",
"     </a>",
"    </li>",
"    <li>",
"     The WHO publications are available through the WHO website. file://apps.who.int/medicinedocs/en/d/Js4927e/ (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     www.ConsumerLabs.com (Accessed on January 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/21\">",
"      Gardiner P. Dietary supplement use in children: concerns of efficacy and safety. Am Fam Physician 2005; 71:1068, 1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/22\">",
"      Jackson CM, Lee DK, Lipworth BJ. The effects of butterbur on the histamine and allergen cutaneous response. Ann Allergy Asthma Immunol 2004; 92:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/23\">",
"      Schapowal A, Study Group. Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of Butterbur extract Ze 339. Phytother Res 2005; 19:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/24\">",
"      Lee DK, Gray RD, Robb FM, et al. A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clin Exp Allergy 2004; 34:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/25\">",
"      Schapowal A, Petasites Study Group. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. BMJ 2002; 324:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/26\">",
"      Ayd��n AA, Zerbes V, Parlar H, Letzel T. The medical plant butterbur (Petasites): analytical and physiological (re)view. J Pharm Biomed Anal 2013; 75:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/27\">",
"      Cao Y, Colegate SM, Edgar JA. Safety assessment of food and herbal products containing hepatotoxic pyrrolizidine alkaloids: interlaboratory consistency and the importance of N-oxide determination. Phytochem Anal 2008; 19:526.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Pharmaceuticals Newsletter, 2012. No 4. file://apps.who.int/medicinedocs/documents/s19772en/s19772en.pdf (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/29\">",
"      Badar VA, Thawani VR, Wakode PT, et al. Efficacy of Tinospora cordifolia in allergic rhinitis. J Ethnopharmacol 2005; 96:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/30\">",
"      Denis G, G&eacute;rard Y, Sahpaz S, et al. [Malarial prophylaxis with medicinal plants: toxic hepatitis due to Tinospora crispa]. Therapie 2007; 62:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/31\">",
"      Chandrasekaran CV, Mathuram LN, Daivasigamani P, Bhatnagar U. Tinospora cordifolia, a safety evaluation. Toxicol In Vitro 2009; 23:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/32\">",
"      Corren J, Lemay M, Lin Y, et al. Clinical and biochemical effects of a combination botanical product (ClearGuard) for allergy: a pilot randomized double-blind placebo-controlled trial. Nutr J 2008; 7:20.",
"     </a>",
"    </li>",
"    <li>",
"     Available in the United States as ClearGuard. Information available at: file://www.nutrilite.com/en-us/Science/NHI/BestOfScience/clear-guard.aspx? (Accessed on March 01, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/34\">",
"      Blom HM, Van Rijswijk JB, Garrelds IM, et al. Intranasal capsaicin is efficacious in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study. Clin Exp Allergy 1997; 27:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/35\">",
"      Bernstein JA, Davis BP, Picard JK, et al. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Ann Allergy Asthma Immunol 2011; 107:171.",
"     </a>",
"    </li>",
"    <li>",
"     In the United States, a product called Sinus Buster is available without a prescription.",
"    </li>",
"    <li>",
"     One such product available in the US and many other countries is called Nasal Ease.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/38\">",
"      Josling P, Steadman S. Use of cellulose powder for the treatment of seasonal allergic rhinitis. Adv Ther 2003; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/39\">",
"      Emberlin JC, Lewis RA. A double blind, placebo-controlled cross over trial of cellulose powder by nasal provocation with Der p1 and Der f1. Curr Med Res Opin 2007; 23:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/40\">",
"      &Aring;berg N, Dahl &Aring;, Benson M. A nasally applied cellulose powder in seasonal allergic rhinitis (SAR) in children and adolescents; reduction of symptoms and relation to pollen load. Pediatr Allergy Immunol 2011; 22:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/41\">",
"      Emberlin JC, Lewis RA. A double blind, placebo controlled trial of inert cellulose powder for the relief of symptoms of hay fever in adults. Curr Med Res Opin 2006; 22:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/42\">",
"      Passalacqua G, Bousquet PJ, Carlsen KH, et al. ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol 2006; 117:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/43\">",
"      Weng Z, Zhang B, Asadi S, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One 2012; 7:e33805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/44\">",
"      Remberg P, Bj&ouml;rk L, Hedner T, Sterner O. Characteristics, clinical effect profile and tolerability of a nasal spray preparation of Artemisia abrotanum L. for allergic rhinitis. Phytomedicine 2004; 11:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/45\">",
"      Mittman P. Randomized, double-blind study of freeze-dried Urtica dioica in the treatment of allergic rhinitis. Planta Med 1990; 56:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/46\">",
"      Takano H, Osakabe N, Sanbongi C, et al. Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. Exp Biol Med (Maywood) 2004; 229:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/47\">",
"      Burrow A, Eccles R, Jones AS. The effects of camphor, eucalyptus and menthol vapour on nasal resistance to airflow and nasal sensation. Acta Otolaryngol 1983; 96:157.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Over-the-counter drugs. Final monograph for OTC nasal decongestant drug products. Federal Register 1994; 41:38408.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/49\">",
"      Volkner JH. [Inhalations of extracts from Gingko biloba in vasomotor rhinitis and in the bronchitic syndrome]. Dtsch Med J 1967; 18:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/50\">",
"      Russo V, Stella A, Appezzati L, et al. Clinical efficacy of a Ginkgo biloba extract in the topical treatment of allergic conjunctivitis. Eur J Ophthalmol 2009; 19:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/51\">",
"      Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res 2010; 24:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/52\">",
"      Bakhshaee M, Jabbari F, Hoseini S, et al. Effect of silymarin in the treatment of allergic rhinitis. Otolaryngol Head Neck Surg 2011; 145:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/53\">",
"      Toxicity. Milk thistle and indinavir. TreatmentUpdate 2002; 14:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/54\">",
"      Doehmer J, Weiss G, McGregor GP, Appel K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro 2011; 25:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/55\">",
"      Bernstein DI, Bernstein CK, Deng C, et al. Evaluation of the clinical efficacy and safety of grapeseed extract in the treatment of fall seasonal allergic rhinitis: a pilot study. Ann Allergy Asthma Immunol 2002; 88:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/56\">",
"      Khmel'kova NG, Makarova VL, Melent'eva EM, et al. [Does laser irradiation affect bronchial obstruction?]. Probl Tuberk 1995; :41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/57\">",
"      Faradzheva NA. [Efficiency of a combination of haloaerosols and helium-neon laser in the multimodality treatment of patients with bronchial asthma]. Probl Tuberk Bolezn Legk 2007; :50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/58\">",
"      Provotorov VM, Chesnokov PE, Kuznetsov SI. [The clinical efficacy of treating patients with nonspecific lung diseases using low-energy laser irradiation and intrapulmonary drug administration]. Ter Arkh 1991; 63:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/59\">",
"      Zamotaev IP, Mamontova LI, Zavolovskaia LI, Rudakova OM. [Effect of laser acupuncture on the pulmonary vascular resistance in patients with obstructive chronic lung diseases]. Klin Med (Mosk) 1991; 69:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/60\">",
"      Morton AR, Fazio SM, Miller D. Efficacy of laser-acupuncture in the prevention of exercise-induced asthma. Ann Allergy 1993; 70:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/61\">",
"      Gruber W, Eber E, Malle-Scheid D, et al. Laser acupuncture in children and adolescents with exercise induced asthma. Thorax 2002; 57:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/62\">",
"      Esaulenko IE, Nikitin AV, Shatalova OL. [The use of laseropuncture in patients with bronchial asthma and concomitant chronic rhinosinusitis]. Vopr Kurortol Fizioter Lech Fiz Kult 2009; :37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/63\">",
"      Nedeljkovi�� M, Ljustina-Pribi�� R, Savi�� K. Innovative approach to laser acupuncture therapy of acute obstruction in asthmatic children. Med Pregl 2008; 61:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/64\">",
"      Tsai YL, Su CC, Lee HS, et al. Symptoms treatment for allergic rhinitis using diode laser: results after 6-year follow-up. Lasers Med Sci 2009; 24:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6953/abstract/65\">",
"      Sandhu AS, Temple RH, Timms MS. Partial laser turbinectomy: two year outcomes in patients with allergic and non-allergic rhinitis. Rhinology 2004; 42:81.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16359 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6953=[""].join("\n");
var outline_f6_50_6953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4359033\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26306525\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4356386\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21282295\">",
"      Barriers to integration with allopathic medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4357371\">",
"      SPECIFIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21282386\">",
"      Traditional Chinese medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15106287\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14493471\">",
"      Ayurveda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26306590\">",
"      Herbal therapies (systemic)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7646786\">",
"      - Choice of brand",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7646793\">",
"      - Children and pregnant or lactating women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4358379\">",
"      - Butterbur (Petasites hybridus)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4358409\">",
"      - Tinofend (Tinospora cordifolia)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12555896\">",
"      - Cinnamon bark, Spanish needle, and acerola",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7646030\">",
"      - Ayurvedic herbal mixes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11050428\">",
"      Nasal sprays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1144540401\">",
"      - Capsaicin (Capsicum annum)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15109033\">",
"      - Cellulose powder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7622228\">",
"      CAM therapies with minimal evidence of efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7645543\">",
"      - Homeopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7646980\">",
"      - Other herbal preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7645328\">",
"      - Laser therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7644800\">",
"      - Other types of treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4359033\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=related_link\">",
"      Chinese herbal medicine for the treatment of allergic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26903?source=related_link\">",
"      Homeopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=related_link\">",
"      Overview of complementary and alternative medicine in pediatrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=related_link\">",
"      Patient information: Alternative medicine (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_50_6954="Treatment of vaginal atrophy";
var content_f6_50_6954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of vaginal atrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/50/6954/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/50/6954/contributors\">",
"     Gloria Bachmann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/50/6954/contributors\">",
"     Richard J Santen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/50/6954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/50/6954/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/50/6954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/50/6954/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/50/6954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal atrophy (also referred to as vulvovaginal atrophy, urogenital atrophy, or atrophic vaginitis) results from estrogen loss and is often associated with vulvovaginal complaints (eg, dryness, burning, dyspareunia) in menopausal women. Urinary frequency and recurrent bladder infections may also occur. The spectrum of adverse consequences makes long-term treatment essential in many women, not only for relief of symptoms, but also for the more troublesome problems that may occur, such as sexual dysfunction, postcoital bleeding, and recurrent urinary tract infections. Treatment options include both hormonal and nonhormonal interventions.",
"   </p>",
"   <p>",
"    Treatment of symptomatic vaginal atrophy is reviewed here. Clinical manifestations and diagnosis of vaginal atrophy, as well as use of estrogen therapy for other menopausal symptoms, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202031\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary indication for treatment of vaginal atrophy is the presence of symptoms that cause distress in a woman who is hypoestrogenic due to menopause or other causes. Vulvovaginal symptoms include: vaginal dryness, burning, pruritus, dyspareunia, vaginal discharge, bleeding, or spotting. Urinary tract symptoms include dysuria, urinary frequency, urethral discomfort, or, infrequently, hematuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to initiating treatment for vaginal atrophy, other conditions should be excluded, in particular (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\", section on 'Differential diagnosis'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with postmenopausal bleeding should be evaluated for endometrial hyperplasia or cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"       \"Evaluation of the endometrium for malignant or premalignant disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with urinary tract symptoms should be evaluated for urinary tract infection or other conditions (interstitial cystitis, urinary tract malignancy), as appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"       \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of asymptomatic women for vaginal atrophy is indicated in some clinical contexts, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to vulvovaginal surgery &ndash; Systemic or vaginal estrogen therapy is given with the goal of optimizing the identification of tissue planes and promoting wound healing. There are few data regarding this use, and it is employed depending upon surgeon preference [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pelvic organ prolapse or urinary incontinence &ndash; Some clinicians treat women with symptomatic pelvic organ prolapse or urinary incontinence with estrogen therapy, although the benefit of this approach is uncertain. However, when pessary use is employed in the management of these conditions, estrogen therapy is beneficial to prevent vaginal abrasions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H6514468#H6514468\">",
"       \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Estrogen therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"       \"Treatment of urinary incontinence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, treatment is indicated in some patients with hypoestrogenism that is not due to menopause (eg, premenarche, lactation, while taking antiestrogenic medications) if symptoms are present (eg, labial adhesions, dyspareunia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link&amp;anchor=H23#H23\">",
"     \"Vulvovaginal complaints in the prepubertal child\", section on 'Labial adhesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=see_link&amp;anchor=H14#H14\">",
"     \"Differential diagnosis of sexual pain in women\", section on 'Postpartum'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202055\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section includes an overview of contraindications; detailed information regarding specific treatments is discussed in the sections below.",
"   </p>",
"   <p>",
"    Topical nonhormonal treatments (lubricants, moisturizers) are contraindicated only in women with an allergic or adverse reaction to a particular product. Mechanical approaches to treatment are contraindicated only in women in whom activities would result in injury.",
"   </p>",
"   <p>",
"    Use of vaginal estrogen therapy requires caution in women with, or who are at increased risk for, some estrogen-dependent tumors. This type of therapy is considered a reasonable option in appropriately screened women following treatment for endometrial or ovarian cancer, but is controversial in women with breast cancer. In addition, testosterone is aromatized to estrogen, and thus, similar precautions are warranted if testosterone therapy is used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H37#H37\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Other postoperative issues'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2203764\">",
"     'Treatment of women with breast cancer'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H25012559#H25012559\">",
"     \"Overview of endometrial carcinoma\", section on 'Postmenopausal estrogen therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H6099467#H6099467\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Postmenopausal estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694711\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For symptoms of vaginal dryness or dyspareunia associated with vaginal atrophy, first-line treatments are nonhormonal vaginal moisturizers and lubricants. If these preparations do not provide adequate symptom relief from the woman&rsquo;s perspective, estrogen therapy may be used for women with no contraindications to such therapy. In addition, sexual activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of vaginal dilators may help maintain a healthy vaginal epithelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOISTURIZERS AND LUBRICANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of vaginal dryness can be managed by regular use of vaginal moisturizing agents with supplemental use of vaginal lubricants for sexual intercourse (",
"    <a class=\"graphic graphic_table graphicRef72389 \" href=\"UTD.htm?7/58/8109\">",
"     table 1",
"    </a>",
"    ). While these agents may improve coital comfort and increase vaginal moisture, they do not reverse most atrophic vaginal changes. Thus, they are useful mostly for women with mild symptoms and those for whom they provide sufficient comfort during coital activity.",
"   </p>",
"   <p>",
"    Vaginal moisturizers are intended for use one or more times per week, not just during sexual activity. Many moisturizer products are available; examples include Replens&reg;, Me Again&trade;, Vagisil&reg; Feminine Moisturizer, Feminease&reg;, and K-Y&reg; SILK-E&reg;.",
"   </p>",
"   <p>",
"    There are few data regarding the efficacy of vaginal moisturizers. A small randomized trial and a small observational study that compared Replens&reg; and a vaginal estrogen preparation reported that relief of vaginal dryness and restoration of normal vaginal pH were similar for both agents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In contrast with estrogen, Replens&reg; does not affect the vaginal maturation index [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/5\">",
"     5",
"    </a>",
"    ]. In our experience, however, estrogen is more effective than vaginal moisturizers.",
"   </p>",
"   <p>",
"    In addition to using a moisturizer on a regular basis, many women also use a lubricant at the time of coitus to decrease irritation. Water soluble products include Astroglide&reg;, Slippery Stuff&reg;, and K-Y&reg; Jelly. Silicone-based lubricants are also available (Pjur&reg; Eros, ID&reg; Millennium), as well as one oil-based product (Elegance Women's Lubricant). Some clinicians counsel that lubricants with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    may result in an increased risk of vulvovaginal candidiasis, but there is no evidence to support this and some data suggest that glycerin (also referred to as glycerol) inhibits candidal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Women should try various products until they find one that meets their needs.",
"   </p>",
"   <p>",
"    Some data suggest that products that result in an acidic pH (in premenopausal women, normal vaginal secretions have a pH of 4.0 to 4.5) are more effective. As an example, a randomized trial of postmenopausal breast cancer survivors with vaginal atrophy found that a gel with added lactic acid (pH 4.0) decreased vaginal irritation, dryness and dyspareunia compared with a gel without lactic acid (pH 7.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/8\">",
"     8",
"    </a>",
"    ]. Further study is needed to validate these results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to women with symptoms of vaginitis\", section on 'Vaginal pH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7630789\">",
"    <span class=\"h1\">",
"     MECHANICAL MEASURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are sexually active with a partner or through masturbation have fewer symptoms related to vaginal atrophy. As an example, a study of 52 postmenopausal women reported significantly less severe vaginal atrophy (as measured by an index of physical examination findings; microscopic or cytologic evaluation was not performed) in those with higher frequency of intercourse (groups were divided into women with 2.42 versus 0.24 episodes of sexual intercourse per week) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/9\">",
"     9",
"    </a>",
"    ]. Serum estrogen levels were not associated with severity of vaginal atrophy. Since vaginal atrophy results in a loss of tissue elasticity, in addition to lubrication, this benefit likely derives from mechanical stretching of the vulvovaginal tissue or increased vaginal blood flow. &nbsp;",
"   </p>",
"   <p>",
"    If appropriate, the clinician may want to alert the patient that sexual activity may improve vaginal function. However, this may not be possible for women in whom dyspareunia precludes sexual activity or who do not have a sexual partner. The type and frequency of sexual activity required to preserve vaginal elasticity and to prevent dyspareunia or stenosis of the vaginal introitus are not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7630851\">",
"    <span class=\"h2\">",
"     Vaginal dilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have contraindications to estrogen therapy and who desire vaginal intercourse may improve vaginal function with the use of vaginal dilators [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/10\">",
"     10",
"    </a>",
"    ]. This is may be particularly effective for women who avoid intercourse due to pain, since vaginal dilators are available in sets of graduated sizes and a narrow dilator can be used initially. Vaginal dilator use can be taught to a woman by her clinician or she can be referred to a pelvic physical therapist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VAGINAL ESTROGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen is the most effective treatment for moderate to severe symptoms of vaginal atrophy. Use of estrogen therapy is appropriate for women with symptoms of vaginal atrophy in the setting of low estrogen levels, provided that there are no contraindications to this therapy (eg, certain women with estrogen-dependent tumors).",
"   </p>",
"   <p>",
"    Adequate estrogen therapy leads to restoration of the normal vaginal acidic pH and microflora, thickening of the epithelium, increased vaginal secretions, and decreased vaginal dryness.",
"   </p>",
"   <p>",
"    In addition, estrogen therapy is associated with urinary tract benefits. These include a reduction in the incidence of urinary tract infections and overactive bladder symptoms. Urge incontinence and stress incontinence, however, do not improve with estrogen therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H29#H29\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Recurrent urinary tract infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the proven success of estrogen therapy, treatment failure warrants evaluation for other etiologies of the patient&rsquo;s symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9004127\">",
"    <span class=\"h2\">",
"     Vaginal versus systemic estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest low dose vaginal estrogen therapy (vaginal administration of a low dose) rather than systemic estrogen therapy (oral, transdermal, or vaginal administration of a higher dose) for women treated solely for vaginal atrophy symptoms. For women receiving systemic estrogen therapy for other menopausal effects (eg, vasomotor symptoms), low dose vaginal therapy may be added if relief of atrophic symptoms is insufficient.",
"   </p>",
"   <p>",
"    We define low dose vaginal estrogen as &le;50 mcg estradiol or &le;0.3 mg conjugated",
"    <span class=\"nowrap\">",
"     estrogens/&le;0.5",
"    </span>",
"    g cream. A preparation containing only 10 micrograms of estradiol (Vagifem) is effective and can be used in place of somewhat higher doses (ie, &gt;50 microgram estradiol or &gt;0.5 g of conjugated estrogen) if there is concern about small amounts of systemic absorption. Of note, some vaginal preparations administer higher doses of estrogen (eg, higher doses of vaginal creams) and some are intended to deliver systemic doses (eg, Femring&reg;, 50 to 100",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/14\">",
"     14",
"    </a>",
"    ]). (See",
"    <a class=\"local\" href=\"#H325508\">",
"     'Ring'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H325522\">",
"     'Creams'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15719545\">",
"     'Systemic absorption'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The preference for low dose vaginal estrogen therapy is based upon efficacy and risk of systemic effects. Vaginal estrogen therapy appears to be more effective than systemic therapy for treatment of vaginal atrophy. A meta-analysis of 58 comparative studies of women with urogenital atrophy found that patient report of symptom relief was significantly higher for vaginal versus oral estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/15\">",
"     15",
"    </a>",
"    ]. The reported efficacy rate is approximately 80 to 90 percent for vaginal therapy and 75 percent for systemic therapy, based upon observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link&amp;anchor=H3#H3\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Systemic estrogen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low dose vaginal therapy also avoids or minimizes systemic estrogen effects. The increased risk of breast cancer with systemic estrogen and progestin and thrombosis with systemic estrogen &ndash;(the risk of thrombosis with progestins is controversial) therapy compared with placebo were best demonstrated by the Women&rsquo;s Health Initiative randomized trial; some of these risks vary depending upon whether a progestin is used in combination with estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=see_link&amp;anchor=H5#H5\">",
"     \"Contraception for women with inherited thrombophilias\", section on 'Progestin-only methods'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential risks of low dose vaginal estrogen therapy have not been evaluated in well-designed studies. Women using low dose vaginal estrogen therapy have serum estradiol levels, using commonly available estrogen assays that are similar to those who are not taking exogenous estrogen. Therefore, systemic risks are possible, but unlikely. However, with ultrasensitive estradiol assays, small increments of estradiol are observed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/22\">",
"     22",
"    </a>",
"    ]. The risks associated with higher dose vaginal therapy are uncertain, but generally require co-administration of a progestin to prevent endometrial hyperplasia. (See",
"    <a class=\"local\" href=\"#H15719545\">",
"     'Systemic absorption'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    On the other hand, the low dose vaginal therapy may not be sufficient for relief of vasomotor symptoms or preservation of bone density. However, one study reported a reduction in bone resorption in postmenopausal women receiving low dose vaginal estradiol (7.5",
"    <span class=\"nowrap\">",
"     mcg/24",
"    </span>",
"    hours), which suggests that a systemic effect is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal estrogen therapy intended for treatment of vaginal atrophy is sometimes referred to as local estrogen therapy. The North American Menopause Society has stated that for urogenital atrophy alone, local vaginal estrogen therapy is generally recommended and that women treated with systemic therapy should be asked whether they have persistent atrophy symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325436\">",
"    <span class=\"h2\">",
"     Vaginal estrogen preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents for vaginal estrogen therapy that are commercially available in the United States are conjugated estrogens (cream) and estradiol (cream, tablet, and ring) (",
"    <a class=\"graphic graphic_table graphicRef58506 \" href=\"UTD.htm?36/48/37643\">",
"     table 2",
"    </a>",
"    ). In Europe and some other countries, estriol cream is also available.",
"   </p>",
"   <p>",
"    The dose and duration of treatment needed to improve symptoms vary across patients, and should be individualized according to the woman's degree of vaginal atrophy symptoms. Low dose vaginal estrogen therapy may be used indefinitely, based upon the low risk of adverse effects, although clinical trials to date have not followed women beyond one year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/11\">",
"     11",
"    </a>",
"    ]. The duration of higher dose vaginal therapy or systemic estrogen therapy should be guided by the risks and benefits of therapy.",
"   </p>",
"   <p>",
"    A systematic review of 19 randomized trials including over 4000 women that investigated local estrogen treatment found that creams, tablets, and rings were all similarly effective in relieving symptoms of vaginal atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/12\">",
"     12",
"    </a>",
"    ]. Systemic absorption, patient preference, convenience, and cost should guide the choice of preparation.",
"   </p>",
"   <p>",
"    In our practice, we use cream for women who have symptomatic vulvar atrophy (eg, fissures), so that cream may also be applied to areas of the vulva affected by atrophy. When the vulvar atrophy improves, we switch to a vaginal tablet or ring, depending upon patient preference. For other women, we start the vaginal tablet and switch to the ring if long-term therapy is desired and if the patient is comfortable with use of the ring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H326092\">",
"    <span class=\"h3\">",
"     Tablet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 10 mcg tablet of estradiol (Vagifem&reg;) for vaginal use for relief of vaginal symptoms became available in the United States in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ]. This dose replaced the 25 mcg tablet that had been in use; the 25 mcg tablet has been discontinued. The tablet is placed in the vagina daily for the first two weeks of use, and then twice weekly thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have demonstrated that the 10 mcg tablet of estradiol is effective for relief of vaginal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ]. Although the 10 mcg estrogen dose is significantly more effective than placebo therapy, it appears to be slightly less effective than the 25 mcg dose for initially inducing maturation, providing relief of vaginal symptoms, decreasing pH, and improving urogenital atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estradiol tablet is inserted into the vagina daily for two weeks and then twice per week thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/11,27\">",
"     11,27",
"    </a>",
"    ]. In one 12-week study of postmenopausal women with baseline serum estradiol concentrations of approximately 7 to 8",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    mean serum estradiol concentrations over a 24-hour period for 25 and 10 mcg estrogen tablets were 23 and 11",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [84.4 and 40.4",
"    <span class=\"nowrap\">",
"     pmol/L],",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15719545\">",
"     'Systemic absorption'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325508\">",
"    <span class=\"h3\">",
"     Ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;A silastic ring impregnated with estradiol (Estring&reg;) delivers estrogen locally to the vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/16,29,30\">",
"     16,29,30",
"    </a>",
"    ]. The ring is designed to release 7.5 mcg of estradiol to the vagina daily for a period of 90 days, at which time the woman or clinician replaces it with a new ring [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In prospective studies of the low dose estradiol ring, symptomatic improvement was comparable to that with orally administered estrogen, and vaginal cytology resembled that of premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/16,30,32-36\">",
"     16,30,32-36",
"    </a>",
"    ]. The ring was well tolerated and did not interfere with intercourse; however, women who had previously undergone a hysterectomy sometimes had problems with ring retention.",
"   </p>",
"   <p>",
"    Another vaginal ring, (Femring&reg;), releases much higher doses of estradiol (50 to 100 mcg per day) and is available for the treatment of both vasomotor and genitourinary atrophy symptoms. This high dose ring is considered systemic, rather than local, vaginal estrogen therapy. (See",
"    <a class=\"local\" href=\"#H9004127\">",
"     'Vaginal versus systemic estrogen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325522\">",
"    <span class=\"h3\">",
"     Creams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two creams for vaginal estrogen therapy are available in the United States. The estrogen dose varies with the amount of cream used; the creams are supplied in a tube with an applicator marked with various doses, so that the patient can measure the prescribed amount [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The two cream preparations contain different types of estrogens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conjugated estrogens (Premarin&reg;; 0.625 mg conjugated",
"      <span class=\"nowrap\">",
"       estrogens/1",
"      </span>",
"      g cream) &ndash; Doses range from 0.5 to 2.0 g of cream. This equals 0.3 to 1.25 mg conjugated estrogens.",
"      <br/>",
"      <br/>",
"      The regimens recommended by the manufacturer for vulvovaginal atrophy are: 0.5 to 2.0 g of cream intravaginally administered in either a continuous regimen (twice weekly) or cyclic regimen (daily for 21 days then off for 7 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Estradiol (Estrace&reg;; 100 mcg",
"      <span class=\"nowrap\">",
"       estradiol/1",
"      </span>",
"      g cream) &ndash; Doses range from 1 to 4 g of cream. This equals 100 to 400 mcg of estradiol.",
"      <br/>",
"      <br/>",
"      The regimen recommended by the manufacturer is: 2 to 4 g of cream intravaginally administered daily for one or one or two weeks, then gradually reduce to half the initial dosage for a similar period [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/40\">",
"       40",
"      </a>",
"      ]. A maintenance dosage of 1 g of cream, one to three times per week may be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we start with daily dosing for two weeks and then change to twice weekly. We do not use a cyclic regimen.",
"   </p>",
"   <p>",
"    It should be noted that the maximal doses of Estrace&reg; indicated on the package insert (2.0 g) produce premenopausal plasma levels of estradiol (premenopausal estradiol ranges from is 40 to 600",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    depending upon the phase of the menstrual cycle) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/41\">",
"     41",
"    </a>",
"    ], and should not be used long-term without an opposing progestin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endometrial assessment. (See",
"    <a class=\"local\" href=\"#H15719545\">",
"     'Systemic absorption'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H323915\">",
"     'Use of an opposing progestin'",
"    </a>",
"    below.). In addition, we use a lower dose of estradiol cream, 50",
"    <span class=\"nowrap\">",
"     mcg/0.5",
"    </span>",
"    g of cream, than recommended by the manufacturer.",
"   </p>",
"   <p>",
"    In women with more severe symptoms, the clinician may start with a larger amount of vaginal estrogen cream (&ge;0.5 g of cream), and then taper to one of the lower estrogen dose options described above. The higher doses of vaginal estrogen raise serum estrogen concentrations and suppress serum gonadotropin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H15719545\">",
"     'Systemic absorption'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The effectiveness of vaginal estrogen cream for treating vaginal atrophy is well established. As an example, in postmenopausal women given 0.5 g conjugated estrogen daily intravaginally, vaginal cytology changed to that of normal premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/29,41,43\">",
"     29,41,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719545\">",
"    <span class=\"h2\">",
"     Systemic absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal estrogen therapy results in estrogen absorption into the circulation, although to a lesser degree than oral or transdermal estrogen therapy. For the same dose of estrogen, a vaginal dose results in lower serum estradiol and estrone levels than oral estrogen (30 percent lower in a study of conjugated estrogens) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/44\">",
"     44",
"    </a>",
"    ]. The absorption of vaginal estrogen depends primarily upon the estrogen dose.",
"   </p>",
"   <p>",
"    The effect of the severity of vaginal atrophy on systemic estrogen absorption is controversial. Some studies have reported that systemic absorption is highest in the first days or weeks of therapy, and then decreases with ongoing treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]; however, a study using highly sensitive estradiol measurements did not support this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/22\">",
"     22",
"    </a>",
"    ]. When present, a higher level of absorption with initial therapy may be due to increased estrogen absorption through the thin atrophic vaginal epithelium, which then cornifies with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/45\">",
"     45",
"    </a>",
"    ]. In women who use the low dose vaginal ring, another possibility is that the device may release a higher dose of estradiol during the first 24 hours of use. This was illustrated in an in vitro study in which the ring released up to 55 mcg during day 1 of testing, versus 7 to 8 mcg during days 2 to 90 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324487\">",
"    <span class=\"h3\">",
"     Comparison of estrogen preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum estradiol levels attained with the low dose preparations are lower than the average level for postmenopausal women, which is approximately 5",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, any amount of estrogen absorption may be clinically relevant in a breast cancer patient, as described below (see",
"    <a class=\"local\" href=\"#H2203764\">",
"     'Treatment of women with breast cancer'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The vaginal estrogen preparations with the lowest systemic absorption are the standard regimens of the 10 mcg estradiol tablet and the 7.5",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    estradiol ring [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/28,42,50,51\">",
"     28,42,50,51",
"    </a>",
"    ]. For vaginal estrogen creams, only the lowest dose of conjugated estrogens (0.3 mg conjugated estrogens in 0.5 g of cream) is a low dose preparation.",
"   </p>",
"   <p>",
"    Other doses of conjugated estrogens cream (&ge;0.625 mg in 1.0 g of cream) and the estradiol vaginal cream are considered higher dose preparations. Higher serum estrogen concentrations lower serum gonadotropin concentrations and may induce endometrial proliferation, which requires the use of a progestin to protect against endometrial neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H323915\">",
"     'Use of an opposing progestin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Systemic estradiol levels for the available vaginal estrogen preparations, used as recommended by the manufacturer, are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estradiol tablet (Vagifem&reg;)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      10 mcg - 3 to 11",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      serum estradiol [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/22,28,52\">",
"       22,28,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      25 mcg &ndash; 9 to 23",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      serum estradiol (this preparation has been discontinued) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/28,52\">",
"       28,52",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low dose estradiol ring (Estring&reg;), 7.5",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      - 5 to 10",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      serum estradiol [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/47,50-52\">",
"       47,50-52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Conjugated estrogens cream (Premarin&reg;), 1 g of cream contains 0.625 mg conjugated estrogens [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Conjugated estrogens contains more than 200 compounds, some of which are estrogenic and some antiestrogenic. The plasma estradiol after use of conjugated estrogens bears no relationship to actual activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estradiol cream (Estrace&reg;), 1 g of cream contains 100 mcg estradiol; 200 mcg of estradiol cream results in a serum estradiol level of approximately 40",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the plasma estradiol assays used for these studies were not sufficiently sensitive to measure the low levels of estradiol present in the serum of many menopausal women and measure compounds other than estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/48\">",
"     48",
"    </a>",
"    ]. For that reason, measurements of estradiol by mass spectrometry assays or ultrasensitive bioassays find much lower levels in postmenopausal women than do radioimmunoassays [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/54\">",
"     54",
"    </a>",
"    ]. When highly sensitive assays were used, increments in estradiol could be detected at very low levels (ie, 5",
"    <span class=\"nowrap\">",
"     pg/ml)",
"    </span>",
"    but not to premenopausal levels (ie, 40 to 600",
"    <span class=\"nowrap\">",
"     pg/ml)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323915\">",
"    <span class=\"h3\">",
"     Use of an opposing progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A progestin is probably",
"    <strong>",
"     not",
"    </strong>",
"    necessary to protect against endometrial hyperplasia or cancer in women treated for vaginal atrophy with low dose preparations (ie, the regimen recommended by the manufacturer of the low dose ring [Estring&reg;] or tablet [Vagifem&reg;], two to four times weekly).",
"   </p>",
"   <p>",
"    The systemic estrogen absorption with use of the vaginal creams (Premarin&reg;, Estrace&reg;) is difficult to quantify precisely and there are few data regarding the risk of endometrial neoplasia with these preparations. Some experts use conjugated estrogens cream 0.25 gm twice weekly without a progestin. However, the most conservative approach is to use an opposing progestin for women treated with vaginal estrogen cream [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/55\">",
"     55",
"    </a>",
"    ]. A typical oral progestin regimen is a daily dose for 10 to 12 consecutive days per month. Examples of progestins that may be used include medroxyprogesterone (eg, 10 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    (eg, 5 to 10 mg), and micronized progesterone (eg, 200 mg). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link&amp;anchor=H17#H17\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Progestin preparations'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The endometrial effect of each of the low dose methods of delivering vaginal estrogen has been evaluated by measuring endometrial thickness by ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/50,51,56\">",
"     50,51,56",
"    </a>",
"    ] or by biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the 10 mcg estradiol tablet (Vagifem&reg;), a prospective study evaluated use for two weeks then twice weekly for 52 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/57\">",
"       57",
"      </a>",
"      ]. Among the 386 women who had an evaluable biopsy 52 weeks after beginning therapy, there was one case of complex hyperplasia without atypia in an individual exposed to the drug for only nine days (suggesting a preexisting abnormality) and one case of endometrioid adenocarcinoma (in whom preexisting disease could not be excluded because the pretreatment biopsy sample was inadequate for analysis). A previous study had supported the endometrial safety of the 25 mcg estradiol vaginal tablet, which has been discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For the low dose estradiol ring (Estring&reg;), 60 postmenopausal women were randomly assigned to receive Estring&reg; or no treatment for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/50\">",
"       50",
"      </a>",
"      ]. Sonographic evaluation found no significant increases in endometrial thickness in either group.",
"     </li>",
"     <li>",
"      For low dose conjugated estrogens cream (Premarin&reg;), a study of 20 women (treated with 0.3 mg of conjugated estrogens, administered vaginally three nights per week for six months) found evidence of endometrial hyperplasia on biopsy in one woman, even though the sonographic endometrial thickness was normal [",
"      <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/56\">",
"       56",
"      </a>",
"      ]. This observation suggests caution, but does not mean that a progestin should be used routinely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence that routine endometrial surveillance is indicated in asymptomatic women receiving low dose vaginal estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/11\">",
"     11",
"    </a>",
"    ]. However, there are no studies of endometrial effects in women who have been treated with low-dose vaginal estrogen therapy for longer than one year; these studies are needed.",
"   </p>",
"   <p>",
"    Regardless of the estrogen dose, women with postmenopausal bleeding should be evaluated, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of an opposing progestin for systemic estrogen therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link&amp;anchor=H17#H17\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Progestin preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719706\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of vaginal estrogen therapy are uncommon. Women may complain of vaginal irritation, vaginal bleeding, or breast tenderness. Women who dislike the messiness of cream may use the tablet or ring.",
"   </p>",
"   <p>",
"    Of note, men exposed to vaginal estrogen cream during sexual intercourse can absorb estrogen, but this is rarely clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2475847\">",
"    <span class=\"h1\">",
"     SELECTIVE ESTROGEN RECEPTOR MODULATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     Ospemifene",
"    </a>",
"    is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in the vagina and appears to have no clinically significant estrogenic effect on the endometrium or breast. Ospemifene was approved by the United States Food and Drug Administration (FDA) in February, 2013 for the treatment of moderate to severe dyspareunia caused by vulvovaginal atrophy; it is anticipated that it will be introduced for clinical use in June, 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women with symptomatic vulvovaginal atrophy that is not relieved with non-pharmacologic therapy, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     ospemifene",
"    </a>",
"    rather than vaginal estrogen therapy for those who cannot (severe arthritis, obesity, vulvodynia) or prefer not to use a vaginal product. The disadvantages of ospemifene compared with vaginal estrogen are need for daily use and systemic side effects (hot flashes, potential risk of thromboembolism). The safety of ospemifene has not been demonstrated in women with a prior history or an increased risk of breast cancer or in women with an increased risk of thromboembolism.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     Ospemifene",
"    </a>",
"    is effective in treating dyspareunia and vaginal dryness in menopausal women with vulvovaginal atrophy compared with placebo; no studies to-date have compared with vaginal estrogen therapy. Two randomized trials found that ospemifene (60 mg orally, 12 weeks of therapy) was significantly more effective than placebo in improving dyspareunia, although the benefit beyond that of placebo was modest [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Severity of dyspareunia was rated with a 4-point scale; in one trial, dyspareunia decreased by 2 to 3 points in 53 percent of women in the treatment group compared with 39 percent of those who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/63\">",
"     63",
"    </a>",
"    ]. The proportion of women for whom dyspareunia was absent or mild was 38 and 25 percent, respectively, compared with 28 and 19 percent in the placebo group. In addition, either 30 or 60 mg of ospemifene was found to significantly decrease vaginal dryness in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hot flushes were the most common adverse effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     ospemifene",
"    </a>",
"    ; in one trial, the rate of hot flushes was 7 percent in the treatment group compared with 3.6 in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/63\">",
"     63",
"    </a>",
"    ]. Ospemifene appears to have a favorable endometrial safety profile. Ospemifene results in an increase in endometrial thickness (0.4 to 0.7 mm in 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]), but studies of one year of use have found no cases of atypical endometrial hyperplasia or endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombotic adverse effects are a potential risk with SERMs. There have been no reports of such complication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     ospemifene",
"    </a>",
"    , but more data are needed to detect this relatively rare complication.",
"   </p>",
"   <p>",
"    Animal and preclinical data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     ospemifene",
"    </a>",
"    has a neutral or inhibitory effect on carcinogenesis in the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Further study is needed to evaluate the safety of ospemifene in women with breast cancer, or whether it may have a protective effect for women at high risk for breast malignancy. &nbsp;",
"   </p>",
"   <p>",
"    A potential benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     ospemifene",
"    </a>",
"    is a reduction in bone turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Use of SERMs for the prevention and treatment of osteoporosis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=see_link\">",
"     \"Selective estrogen receptor modulators for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER TYPES OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation is recommended for its general health benefits and because women who smoke cigarettes are relatively estrogen-deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative and complementary therapies, including oral vitamin D and vaginal vitamin E, have been proposed, but efficacy data are limited",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discordant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Women who use an alternative or complementary treatment should check with the manufacturer regarding whether the product contains estrogen or other hormones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2203764\">",
"    <span class=\"h1\">",
"     TREATMENT OF WOMEN WITH BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal atrophy symptoms are a common complaint among sexually active women with breast cancer, particularly those on endocrine treatments (aromatase inhibitors or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ). A study of 97 women with breast cancer reported moderate or severe symptoms of vaginal atrophy in 58 percent of women on aromatase inhibitors and 32 percent of those on tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/75\">",
"     75",
"    </a>",
"    ]. It should be noted that in premenopausal women, tamoxifen exerts anti-estrogenic effects on the vagina. In postmenopausal women, it exerts weak estrogenic effects on the vagina, but some women treated with tamoxifen still experience symptoms of urogenital atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/76-79\">",
"     76-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonhormonal options are the first line of treatment of vaginal atrophy in women with breast cancer (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Moisturizers and lubricants'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7630789\">",
"     'Mechanical measures'",
"    </a>",
"    above). Few studies have evaluated these treatments in women with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     Pilocarpine",
"    </a>",
"    , a cholinergic agonist used to treat Sj&ouml;gren's syndrome, was investigated for this indication, but was",
"    <strong>",
"     not",
"    </strong>",
"    found to improve vaginal dryness compared with placebo in a randomized trial of 201 women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/80\">",
"     80",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    There are few data regarding the safety of vaginal estrogen therapy in women with breast cancer. No increase in the risk of recurrence was found in a prospective cohort study of 1472 women with breast cancer included 69 women treated with vaginal estrogen for an average of one year (range 0.1 to 5 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/81\">",
"     81",
"    </a>",
"    ]. The study did not report recurrence rates by stage or hormone receptor status. &nbsp;",
"   </p>",
"   <p>",
"    There is also a lack of data about whether the efficacy of endocrine therapy is impacted by concurrent low-dose vaginal estrogen therapy. We suggest",
"    <strong>",
"     not",
"    </strong>",
"    using vaginal estrogen therapy for women who are using aromatase inhibitor therapy for breast cancer. The aim of this therapy is to maximally reduce the systemic estrogen level, and this level is slightly increased with use of vaginal estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/82\">",
"     82",
"    </a>",
"    ]. In women taking aromatase inhibitors, this was evaluated in a study in which six women were treated for 12 weeks with Vagifem&reg; 25 mcg [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/83\">",
"     83",
"    </a>",
"    ]. The suppression of serum estradiol (E2) concentrations achieved with the aromatase inhibitor (E2 &lt;5",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    [1.4",
"    <span class=\"nowrap\">",
"     pg/mL])",
"    </span>",
"    was reversed by the vaginal estrogen at two weeks (mean E2: 72",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    [19.6",
"    <span class=\"nowrap\">",
"     pg/mL]),",
"    </span>",
"    and somewhat less so at four weeks (mean E2: 35",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    [9.5",
"    <span class=\"nowrap\">",
"     pg/mL])",
"    </span>",
"    when measured by a highly sensitive assay. Some data suggest that use of topical testosterone in women on aromatase inhibitors does not increase serum estradiol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regarding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , in the prospective study cited in a preceding paragraph, 48 percent of women who used vaginal estrogen therapy were treated with tamoxifen, but it is unknown whether these therapies were concurrent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/81\">",
"     81",
"    </a>",
"    ]. There are no other data regarding use of vaginal estrogen in women on tamoxifen. In our opinion, it is reasonable to treat women on tamoxifen who have symptomatic vaginal atrophy with low dose vaginal estrogen. Under these circumstances, the small amounts of absorbed estrogen are likely blocked by the systemic anti-estrogen actions of tamoxifen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In summary, use of low dose vaginal estrogen in women with breast cancer is reasonable in women who have failed non-hormonal treatments and who are at a low risk of recurrence and who are not on aromatase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/82,85,86\">",
"     82,85,86",
"    </a>",
"    ]. Vaginal estrogen therapy should be initiated in these patients",
"    <strong>",
"     only",
"    </strong>",
"    after consultation with the patient's oncologist and after comprehensive counseling of the patient about potential risks. Use of low dose vaginal estrogens in women receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    might be considered, again after full discussion with the patient and oncologist.",
"   </p>",
"   <p>",
"    Use of estriol rather than estradiol has been suggested for women with breast cancer, since its metabolic clearance is more rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/82\">",
"     82",
"    </a>",
"    ]. Vaginal estriol preparations (Ortho-gynest&reg; pessary, Ortho-gynest&reg; cream, and Ovestin&reg; cream) are available in Europe, but not in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of vaginal testosterone therapy in women with breast cancer is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/50/6954/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/2/13346?source=see_link\">",
"       \"Patient information: Atrophic vaginitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"       \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal atrophy (also referred to as vulvovaginal atrophy, urogenital atrophy, or atrophic vaginitis) caused by estrogen loss often results in vaginal complaints (eg, dryness, burning, dyspareunia) that cause distress in menopausal women. Urinary frequency and recurrent bladder infections may also occur. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary indication for treatment of vaginal atrophy is the relief of bothersome symptoms in a menopausal woman who is distressed by them. (See",
"      <a class=\"local\" href=\"#H2202031\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular sexual activity helps maintain vaginal health. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sexual activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As first line therapy for symptoms of vaginal atrophy, we suggest regular use of vaginal moisturizing agents supplemented by water-based lubricants during vaginal intercourse rather than treatment with hormonal agents or vaginal dilator therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Moisturizers and lubricants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women in whom vaginal moisturizers and lubricants are insufficient and who are treated solely for vaginal atrophy, and not for other menopausal symptoms, we recommend low dose vaginal estrogen rather than systemic estrogen therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H325436\">",
"       'Vaginal estrogen preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with symptomatic vulvovaginal atrophy that is not relieved with non-pharmacologic therapy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"       ospemifene",
"      </a>",
"      rather than vaginal estrogen for those who cannot (severe arthritis, obesity, vulvodynia) or prefer not to use a vaginal product (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The safety of ospemifene has not been demonstrated in women with a prior history or an increased risk of breast cancer or in women with an increased risk of thromboembolism. (See",
"      <a class=\"local\" href=\"#H2475847\">",
"       'Selective estrogen receptor modulators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of the vaginal delivery system (tablet, ring, cream) depends on patient preference; all are similarly effective (",
"      <a class=\"graphic graphic_table graphicRef58506 \" href=\"UTD.htm?36/48/37643\">",
"       table 2",
"      </a>",
"      ). The ring and the 10 mcg estradiol tablet provide the lowest dose options for vaginal estrogen therapy.",
"     </li>",
"     <li>",
"      For women treated with the low dose vaginal estrogen ring (7.5",
"      <span class=\"nowrap\">",
"       mcg/day)",
"      </span>",
"      or tablet (10 mcg two to four times weekly) or a minidose of conjugated estrogens cream (0.25 mg twice weekly), we don&rsquo;t routinely treat with an opposing progestin to prevent endometrial neoplasia. For women who receive higher doses of conjugated estrogens cream (&gt;0.25 gm twice weekly) or any dose of estradiol cream, we suggest treatment with a progestin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H325436\">",
"       'Vaginal estrogen preparations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H323915\">",
"       'Use of an opposing progestin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-line treatment of symptoms of vaginal atrophy in women with breast cancer includes non-hormonal options (lubricants, moisturizers). We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using vaginal estrogen therapy for women who are on aromatase inhibitors for breast cancer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Use of low dose vaginal estrogen in other women with breast cancer who are at a low risk of recurrence is reasonable. This should be only done in collaboration with the patient's oncologist and after explanation of potential risks to the patient. (See",
"      <a class=\"local\" href=\"#H2203764\">",
"       'Treatment of women with breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/1\">",
"      Pushkar' DIu, D'iakov VV, Godunov BN, Gvozdev MIu. [Ovestin in preparation for transvaginal surgeries]. Urologiia 2002; :34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/2\">",
"      Vesna A, Neli B. Benefit and safety of 28-day transdermal estrogen regimen during vaginal hysterectomy (a controlled trial). Maturitas 2006; 53:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/3\">",
"      Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996; 23:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/4\">",
"      Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994; 61:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/5\">",
"      van der Laak JA, de Bie LM, de Leeuw H, et al. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol 2002; 55:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/6\">",
"      Wiggins DL, Dizon DS. Dyspareunia and vaginal dryness. SRM 2008; 6:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/7\">",
"      Strandberg KL, Peterson ML, Lin YC, et al. Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Antimicrob Agents Chemother 2010; 54:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/8\">",
"      Lee YK, Chung HH, Kim JW, et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011; 117:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/9\">",
"      Leiblum S, Bachmann G, Kemmann E, et al. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 1983; 249:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/10\">",
"      Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011; 8:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/11\">",
"      North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/12\">",
"      Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; :CD001500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/13\">",
"      Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95:s1.",
"     </a>",
"    </li>",
"    <li>",
"     Pharmaceutical Approvals Monthly May 2003; 8:19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/15\">",
"      Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998; 92:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/16\">",
"      Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/17\">",
"      Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005; 105:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/18\">",
"      Long CY, Liu CM, Hsu SC, et al. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006; 13:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/19\">",
"      Barlow DH, Cardozo LD, Francis RM, et al. Urogenital ageing and its effect on sexual health in older British women. Br J Obstet Gynaecol 1997; 104:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/20\">",
"      Simuni�� V, Banovi�� I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003; 82:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/21\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/22\">",
"      Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002; 9:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/23\">",
"      Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. Am J Obstet Gynecol 1997; 177:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/24\">",
"      Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008; 111:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/25\">",
"      Simon J, Nachtigall L, Gut R, et al. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008; 112:1053.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.vagifemhcp.com/Content/files/vagifem-pi.pdf (Accessed on February 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/27\">",
"      Mainini G, Scaffa C, Rotondi M, et al. Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17beta-estradiol vaginal tablets. Clin Exp Obstet Gynecol 2005; 32:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/28\">",
"      Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002; 99:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/29\">",
"      Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am 1994; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/30\">",
"      Henriksson L, Stjernquist M, Boquist L, et al. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994; 171:624.",
"     </a>",
"    </li>",
"    <li>",
"     file://media.pfizer.com/files/products/uspi_estring.pdf (Accessed on February 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/32\">",
"      Henriksson L, Stjernquist M, Boquist L, et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996; 174:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/33\">",
"      Bachmann G. The estradiol vaginal ring--a study of existing clinical data. Maturitas 1995; 22 Suppl:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/34\">",
"      Bachman, GA. A new option for managing urogenital atrophy in postmenoapussal women. Contemp Obstet Gynecol 1997; 42:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/35\">",
"      Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency--a pharmacokinetic and pharmacodynamic study. Maturitas 1992; 15:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/36\">",
"      Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     file://labeling.pfizer.com/showlabeling.aspx?id=132 (Accessed on February 25, 2011).",
"    </li>",
"    <li>",
"     file://www.wcrx.com/pdfs/pi/pi_ppi_estrace_cream.pdf (Accessed on February 25, 2011).",
"    </li>",
"    <li>",
"     file://labeling.pfizer.com/showlabeling.aspx?id=132 (Accessed on April 12, 2011).",
"    </li>",
"    <li>",
"     file://www.wcrx.com/pdfs/pi/pi_ppi_estrace_cream.pdf (Accessed on April 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/41\">",
"      Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983; 57:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/42\">",
"      Rioux JE, Devlin C, Gelfand MM, et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/43\">",
"      Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/44\">",
"      Dorr MB, Nelson AL, Mayer PR, et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil Steril 2010; 94:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/45\">",
"      Pschera H, Hjerpe A, Carlstr&ouml;m K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 beta and progesterone in postmenopausal women. Gynecol Obstet Invest 1989; 27:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/46\">",
"      Holmgren PA, Lindskog M, von Schoultz B. Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy. Maturitas 1989; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/47\">",
"      Schmidt G, Andersson SB, Nordle O, et al. Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol Obstet Invest 1994; 38:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/48\">",
"      Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006; 91:3791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/49\">",
"      Guthrie JR, Dennerstein L, Taffe JR, et al. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. Climacteric 2004; 7:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/50\">",
"      Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. Am J Obstet Gynecol 2002; 186:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/51\">",
"      Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/52\">",
"      Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric 2010; 13:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/53\">",
"      Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978; 298:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/54\">",
"      Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007; 16:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/55\">",
"      Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009; 16:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/56\">",
"      Handa VL, Bachus KE, Johnston WW, et al. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994; 84:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/57\">",
"      Simon J, Nachtigall L, Ulrich LG, et al. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010; 116:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/58\">",
"      Ware MD, Thomas EK, Notelovitz M. Serum hormone levels in men exposed to vaginal oestrogen cream: a preliminary report. Maturitas 1985; 7:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/59\">",
"      DiRaimondo CV, Roach AC, Meador CK. Gynecomastia from exposure to vaginal estrogen cream. N Engl J Med 1980; 302:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/60\">",
"      Hurst BS, Jones AI, Elliot M, et al. Absorption of vaginal estrogen cream during sexual intercourse: a prospective, randomized, controlled trial. J Reprod Med 2008; 53:29.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.shionogi.com/pdf/Osphena-PressRelease.pdf (Accessed on March 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/62\">",
"      Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/63\">",
"      Portman DJ, Bachmann GA, Simon JA, and the Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/64\">",
"      Rutanen EM, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003; 10:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/65\">",
"      Simon JA, Lin VH, Radovich C, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/66\">",
"      Goldstein S, Bachmann G, Lin V, et al.. Endometrial safety profile of ospemifene 60 mg when used for long-term treatment of vulvar and vaginal atrophy for up to 1 year (abstract). Climacteric 2011; 14:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/67\">",
"      Wurz GT, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/68\">",
"      Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause 2012; 19:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/69\">",
"      Komi J, Heikkinen J, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004; 18:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/70\">",
"      Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006; 24:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/71\">",
"      Tansavatdi K, McClain B, Herrington DM. The effects of smoking on estradiol metabolism. Minerva Ginecol 2004; 56:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/72\">",
"      Castelo-Branco C, Cancelo MJ, Villero J, et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005; 52 Suppl 1:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/73\">",
"      Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. Eur Rev Med Pharmacol Sci 2008; 12:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/74\">",
"      Yildirim B, Kaleli B, D&uuml;zcan E, Topuz O. The effects of postmenopausal Vitamin D treatment on vaginal atrophy. Maturitas 2004; 49:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/75\">",
"      Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol 2011; 204:26.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/76\">",
"      Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000; 92:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/77\">",
"      Winneker RC, Harris HA. Progress and prospects in treating postmenopausal vaginal atrophy. Clin Pharmacol Ther 2011; 89:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/78\">",
"      Vardy MD, Lindsay R, Scotti RJ, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 2003; 189:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/79\">",
"      McGonigle KF, Smith DD, Marx HF, et al. Uterine effects of tamoxifen: a prospective study. Int J Gynecol Cancer 2006; 16:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/80\">",
"      Loprinzi CL, Balcueva EP, Liu H, et al. A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA. J Support Oncol 2011; 9:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/81\">",
"      Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/82\">",
"      Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009; 12:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/83\">",
"      Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/84\">",
"      Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011; 16:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/85\">",
"      B&eacute;lisle S, Blake J, Basson R, et al. Canadian Consensus Conference on menopause, 2006 update. J Obstet Gynaecol Can 2006; 28:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/86\">",
"      Loibl S, Lintermans A, Dieudonn&eacute; AS, Neven P. Management of menopausal symptoms in breast cancer patients. Maturitas 2011; 68:148.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01122342?term=testosterone+and+vaginal+atrophy+and+breast+cancer&amp;rank=1 (Accessed on January 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/50/6954/abstract/88\">",
"      Melisko, M, Rugo, H, DeLuca, A, et, al. A Phase II Study of Vaginal Testosterone Cream (TEST) vs. Estring for Vaginal Dryness or Decreased Libido in Women with Early Stage Breast Cancer (BC) Treated with Aromatase Inhibitors (AIs) (abstract). Cancer Res 2009; 69:nr 5038.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5443 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6954=[""].join("\n");
var outline_f6_50_6954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202031\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202055\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2694711\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOISTURIZERS AND LUBRICANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7630789\">",
"      MECHANICAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sexual activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7630851\">",
"      Vaginal dilators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VAGINAL ESTROGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9004127\">",
"      Vaginal versus systemic estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H325436\">",
"      Vaginal estrogen preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H326092\">",
"      - Tablet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H325508\">",
"      - Ring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H325522\">",
"      - Creams",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15719545\">",
"      Systemic absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H324487\">",
"      - Comparison of estrogen preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H323915\">",
"      - Use of an opposing progestin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15719706\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2475847\">",
"      SELECTIVE ESTROGEN RECEPTOR MODULATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER TYPES OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2203764\">",
"      TREATMENT OF WOMEN WITH BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5443\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5443|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/58/8109\" title=\"table 1\">",
"      Vaginal lubricants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/48/37643\" title=\"table 2\">",
"      Vaginal estrogen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=related_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=related_link\">",
"      Contraception for women with inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=related_link\">",
"      Differential diagnosis of sexual pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/2/13346?source=related_link\">",
"      Patient information: Atrophic vaginitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_50_6955="Indic for karyotype";
var content_f6_50_6955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Decision tree - Indications for sending tissue for cytogenetics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Clinician request",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Third loss, does not need to be consecutive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-immune hydrops fetalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe growth restriction (&lt;3rd percentile by best estimate of gestational age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One anomaly in 1st trimester loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two anomalies for all other losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single, \"specific\", anomaly (eg, complete common AV canal defect)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Known maternal or paternal balanced translocation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verification of abnormal amniotic fluid-based karyotype",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6955=[""].join("\n");
var outline_f6_50_6955=null;
var title_f6_50_6956="Pseudoallergen free diet";
var content_f6_50_6956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pseudoallergen free diet - prohibited foodstuffs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Foodstuff",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Additives",
"      </td>",
"      <td>",
"       E100-E1518, preservatives or artificial colors, gelling agents, thickening matter, humectant, emulsifiers, flavor potentiators, antioxidants, separating agents, sweeteners, baking agents, modified starches, foaming agents, stabilizers, flavoring agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spices and herbs",
"      </td>",
"      <td>",
"       (Salt and chives allowed) Avoid all others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Egg products",
"      </td>",
"      <td>",
"       Eggs, pasta made with eggs, cake, biscuits, mayonnaise",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meat and seafood",
"      </td>",
"      <td>",
"       Smoked meats, seafood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vegetables",
"      </td>",
"      <td>",
"       Tomatoes, artichokes, peas, mushrooms, spinach, rhubarb, olives, sweet peppers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fruit",
"      </td>",
"      <td>",
"       Fresh fruits, dried fruits, and fruit juices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Breads",
"      </td>",
"      <td>",
"       Breads with additional grains, herbs, or other such added ingredients. Packaged bread is preferrable to bakery breads, because the ingredients are listed on the label.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Miscellaneous, candies",
"      </td>",
"      <td>",
"       Alcohol, herbal teas, margarine, sesame, potato chips, chewing gum, candy",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A pseudoallergen free diet consists of only fresh foods that are NOT listed above, or deep-frozen versions of these foods without any additives. All preserved and processed foods should be avoided. Chemical and common names for additives listed by E number above may be found online at www.food.gov.uk/safereating/chemsafe/additivesbranch/enumberlist.",
"    <br>",
"     The author of this review and the editors of UpToDate do not routinely recommend this diet to patients with chronic urticaria, for the reasons discussed in the text. However, there may be patients who are interested in this information.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Adapted from: Magerl, M, Pisarevskaja, D, Scheufele, R, et al. Effects of a pseudoallergen free diet on chronic spontaneous urticaria: a prospective trial. Allergy 2010; 65:78.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6956=[""].join("\n");
var outline_f6_50_6956=null;
var title_f6_50_6957="Etiology of macrocephaly";
var content_f6_50_6957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected causes of macrocephaly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased brain (megalencephaly)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Anatomic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Familial megalencephaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neurocutaneous disorders (eg, neurofibromatosis, tuberous scleorsis, linear sebaceous nevus syndrome, Sturge-Weber syndrome, Klippel-Trenaunay-Weber syndrome, nevoid basal call carcinoma syndrome [Gorlin syndrome])",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Autism spectrum disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Achondroplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cerebral gigantism (Sotos syndrome)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fragile X syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            PTEN hamartoma syndromes (eg, Cowden syndrome, Bannayan-Riley-Ruvalcaba)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leukodystrophies (eg, Alexander, Canavan, megalencephalic leukoencephalopathy)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lysosomal storage disorders (eg, Tay-Sachs, mucopolysaccharidosis, gangliosidosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased cerebrospinal fluid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrocephalus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benign enlargement of the subarachnoid space",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydranencephaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Choroid plexus papilloma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased blood",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemorrhage (intraventricular, subdural, epidural, subarachnoid)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arteriovenous malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased bone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bone marrow expansion (eg, thalassemia major)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary bone disorders (eg, skeletal and cranial dysplasias such as achondroplasia, osteogenesis imperfecta, cleidocranial dysostosis, metaphyseal dysplasia, osteopetrosis, hyperphosphatasia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased intracranial pressure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic (pseudotumor cerebri)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infection or inflammation (eg, meningitis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxins (eg, lead)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metabolic abnormalities (eg, vitamin A deficiency or excess, galactosemia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Mass lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial abscess",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *&nbsp;Please see the topic review on hydrocephalus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6957=[""].join("\n");
var outline_f6_50_6957=null;
var title_f6_50_6958="Change hemoglobin with IUD";
var content_f6_50_6958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Change in hemoglobin during 5 years of use",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 361px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pakarinen, P, Luukkainen, T. Treatment of menorrhagia with an LNG-IUS. Contraception 2007; 75:5118. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6958=[""].join("\n");
var outline_f6_50_6958=null;
var title_f6_50_6959="Amplatzer device ASD";
var content_f6_50_6959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/72126/teecampl_conv.mp4?title=Amplatzer+device+ASD\" style=\"width:383px;height:276px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amplatzer device for atrial septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram with color flow Doppler shows an Amplatzer device (arrow) which closes an atrial septal defect. With color flow Doppler there is no blood flow across the device, although a small amount of blood flow can be appreciated within the device itself.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_50_6959=[""].join("\n");
var outline_f6_50_6959=null;
